Programmable pharmaceutical compositions for chrono drug release

ABSTRACT

The present disclosure provides programmable osmotic-controlled oral compositions providing delayed release of a therapeutically acceptable amount of a drug. In certain embodiments, the programmable osmotic-controlled compositions of the disclosure provide a lag time that is independent of the presence or absence of food, type of food, pH, gastric emptying, and volume of gastric fluid. The programmable osmotic-controlled oral compositions of the disclosure comprise a multilayer core comprising a drug for controlled release, wherein the core is coated with a semipermeable membrane comprising an orifice and, optionally, an immediate release coating, comprising a drug for immediate release, over the semipermeable membrane. The multilayered core comprises a pull layer containing the drug and a push layer. The pull layer comprises at least two layers: a placebo layer for providing a desired lag time for the drug release; and an active layer containing the drug and providing a delayed controlled release of the drug. The compositions of the disclosure can be programmed to provide a desired and precise lag time, and release drug, after the lag time, at a rhythm, e.g., that matches the human circadian rhythm of a condition&#39;s symptoms and/or of the individual being treated in the application of the therapy to optimize therapeutic outcome and minimize side effects.

1. RELATED APPLICATIONS

This application claims priority to U.S. Provisional Patent ApplicationNos. 62/638,667, filed Mar. 5, 2018, and 62/760,771, filed Nov. 13,2018, the disclosures of which are hereby incorporated by referenceherein in their entireties.

2. TECHNICAL FIELD

The presently disclosed subject matter relates to programmableosmotic-controlled oral compositions providing delayed controlledrelease of a drug. The osmotic-controlled oral compositions of thedisclosure can be programmed to provide a desired and precise lag time,thereby releasing drug, after the lag time, at a rhythm, e.g., thatmatches the human circadian rhythm of a condition's symptoms and/or ofthe individual being treated in the application of the therapy, tooptimize therapeutic outcome and minimize side effects. The programmableosmotic-controlled compositions of the disclosure can provide a lag timethat is independent of the presence or absence of food, type of food,pH, gastric emptying, and volume of gastric fluid.

3. BACKGROUND

Attention deficit disorders, e.g., ADHD, are among the most commondevelopmental disorders in children and are characterized by symptomssuch as impulsiveness, hyperactivity, and inattentiveness. Hyperactivityis common in children with ADHD. Stimulant medications are widely usedas a pharmacological treatment for ADHD/ADD. Stimulant medicationsapproved by the FDA include methylphenidate, and salts and isomers ofamphetamine. One major challenge of treating ADHD and otherstimulant-responsive conditions is delivering and maintaining aneffective stimulant concentration in patients, particularly children,throughout the day, in particular during the morning hours whencognitive abilities and concentration are needed for school, work, orextracurricular activities, and during the late afternoon or eveningwhen students often do homework. Early morning symptom control,including getting the children ready for school, is a major challengefor parents and caregivers of children suffering from ADHD/ADD.Typically, stimulant-based medications are dosed two hours prior tobeginning an early morning routine, with an onset of treatment effectusually about two hours after administration. Such medications requiretwice-daily administration and cause compliance issues. JORNAY PM™, acommercially available product of methylphenidate (IronshorePharmaceuticals and Development Inc., NDA#209311), has been approved bythe FDA for the treatment of ADHD in patients six years and older.JORNAY PM™ is a methylphenidate formulation that is to be administeredin the evening in an attempt to improve ADHD symptoms in the earlymorning and throughout the day. However, drug release from theformulation can be affected by pH, food, and gastric transit time, witha potential for variable drug release during the night and predawnhours, leading to insomnia.

Extended release of a drug from an oral dosage form can be affected byhydrodynamic conditions in the GI tract that are associated with, e.g.,pH and presence of food in the stomach. Osmotic-controlled oral drugdelivery systems (OROS) known in the art provide controlled extendedrelease of a drug with zero-order kinetics. The OROS drug deliverysystem is an advanced drug delivery technology that uses osmoticpressure as a driving force for controlled delivery of active agents.Such systems provide a constant release rate of a drug over an extendedperiod of time. OROS delivery systems utilize osmotic pressure togenerate a driving force for imbibing fluid into a compartment enclosedpartially or completely by a semipermeable membrane that permits freediffusion of a fluid but not solutes, including active or osmoticagents.

Osmotic-controlled compositions comprising a drug in a mixture withosmotically active agents/osmotic agents are known in the art (e.g.,U.S. Pat. Nos. 4,327,725; 4,612,008; 4,783,337; 5,082,668). Thesecompositions comprise a bilayer tablet core surrounded by asemipermeable membrane with an orifice. The first component layer, thepull layer, comprises a drug(s) in a mixture of excipients that forms adeliverable drug formulation within the compartment. A second componentlayer, the push layer, comprises osmotic agents, e.g., swellablehydrophilic polymers and osmogens. The swellable hydrophilic polymers inthe second component layer comprise one or more high molecular weighthydrophilic polymers that swell as fluid is imbibed. The secondcomponent layer is referred to as “push layer” because as fluid isimbibed, the hydrophilic polymer swells and pushes against thedeliverable drug formulation in the first component layer, therebyfacilitating release of drug formulation from the first layer through anorifice in the semipermeable membrane at a substantially constant rate.

Although suitable for providing a controlled release of drugs withvarious solubilities, osmotic-controlled compositions known in the artare not entirely suitable for being programmed as controlled releasecompositions that 1) delay the release of a drug/provide a lag time forat least about 4 hours, 2) provide a lag time that is independent of thepresence or absence of food, type of food, pH, gastric emptying, andvolume of gastric fluid, 3) provide a plasma concentration of the activepharmaceutical ingredient during the lag time that is less than about10% of a maximum concentration (Cmax), 4) provide pH-independent drugrelease, after the lag time, at a rhythm that matches the humancircadian rhythm of a condition's symptoms and/or of the individualbeing treated in the application of the therapy, and 5) provide completedrug recovery at a desired time. A typical osmotic-controlled systemknown in the art provides a short lag time of about 30-120 minutesduring which the system hydrates before zero-order delivery from thesystem is obtained.

Accordingly, there remains a need to develop osmotic-controlled systemsthat can provide controlled release of a drug at a desired rate andtime, while providing complete drug recovery. There remains a need todevelop compositions that can be programmed for treating conditions thatrequire delayed controlled release of a drug, e.g., compositions fortreating central nervous system (CNS) disorders, asthma, arthritis,congestive heart failure, myocardial infarction, stroke, cancer, pepticulcer, narcolepsy, epilepsy, migraine, pain, etc., wherein the risk andsymptoms of the disease vary predictably over time. In particular, thereremains a need to develop compositions that can be programmed to controlattention disorders, which require improvement in symptoms in the earlymorning and throughout the day.

4. SUMMARY

The presently disclosed subject matter provides an osmotic-controlledoral pharmaceutical composition providing delayed release of atherapeutically effective amount of an active pharmaceutical ingredient,the composition comprising a multilayered core comprising the activepharmaceutical agent and an osmogen, and a semipermeable membrane,containing an orifice, over the core. In certain embodiments, when thecomposition is placed in a dissolution medium comprising about 900 ml ofaqueous solution of about 0.01N HCl at a pH of about 2.0, for up to 24hours, the composition provides a lag time of at least about 6 hoursduring which the composition releases no more than 10% of the activepharmaceutical ingredient, followed by extended release of the activepharmaceutical agent for about 10-16 hours, as measured in USP

Apparatus II at 37° C. and agitation at 50 rpm. In certain embodiments,the composition provides a drug recovery of at least about 90% at about22 hours from the time of administration into the dissolution medium,and exhibits minimal variability in the lag time with variations in pH,volume of the dissolution medium, and/or the viscosity of thedissolution medium.

In certain embodiments, the multilayered core comprises a placebo layer,an active layer, and a push layer, and the placebo layer issubstantially free of osmogen and disintegrant.

In certain embodiments, the placebo layer comprises at least one lowmolecular weight polyethylene oxide polymer and is substantially free ofosmogen and disintegrant.

In certain embodiments, the active layer comprises an activepharmaceutical agent and at least one low molecular weight polyethyleneoxide polymer.

In certain embodiments, the push layer comprises at least one highmolecular weight polyethylene oxide polymer and an osmogen.

In certain embodiments, the semipermeable membrane comprises apH-independent water-insoluble polymer and a pH-independent pore formerat a polymer to pore former ratio of between about 80:20 and about99.5:0.5.

In certain embodiments, the semipermeable membrane comprises apH-independent water-insoluble polymer and a pH-independent pore formerat a polymer to pore former ratio of between about 90:10 and 99.5:0.5.

In certain embodiments, the semipermeable membrane is applied with acoating weight gain of about 12.5 wt % of the multilayered core.

In certain embodiments, the pH-independent water-insoluble polymer inthe semipermeable membrane comprises polymers selected from the groupconsisting of cellulose acetate, cellulose acetate butyrate, andcellulose triacetate.

In certain embodiments, the pH-independent water-insoluble polymer iscellulose acetate.

In certain embodiments, the pore former is selected from the groupcomprising polyethylene glycol, hydroxypropyl cellulose, polyvinylpyrolidone, polyvinyl acetate, mannitol, and methyl cellulose,poloxamer, triethyl citrate, triacetin, hydroxypropyl methylcellulose,glycerol, and combinations thereof.

In certain embodiments, the pore former is polyethylene glycol and/orpoloxamer.

In certain embodiments, the semipermeable membrane further comprises atleast one plasticizer selected from the group consisting of polyethyleneglycols, triethyl citrate, triacetin, diethyl tartrate, and combinationsthereof.

In certain embodiments, the water-insoluble polymer is cellulose acetateand the pore former is polyethylene glycol or poloxamer.

In certain embodiments, the delayed release comprises a delayed extendedrelease or a delayed chrono release.

In certain embodiments, the active layer comprises an immediate releaselayer and an extended release layer to provide a delayed chrono releaseof the active pharmaceutical ingredient.

In certain embodiments, the layers in the multilayered core are arrangedin the following order: a placebo layer in fluid communication with theorifice in the semipermeable membrane, the active layer, and the pushlayer, wherein the push layer is facing away from the orifice.

In certain embodiments, the low molecular weight polyethylene oxidepolymer in the placebo layer has an average molecular weight of about100K, about 200K, about 300K, about 600K, about 900K, or intermediatevalues thereof.

In certain embodiments, the low molecular weight polyethylene oxidepolymer in the placebo layer has an average molecular weight of at leastabout 600K.

In certain embodiments, the low molecular weight polyethylene oxidepolymer in the placebo layer has an average molecular weight of about900K.

In certain embodiments, the low molecular weight polyethylene oxidepolymer in the active layer has an average molecular weight of about100K, about 200K, about 300K, about 600K, about 900K, or intermediatevalues thereof.

In certain embodiments, the low molecular weight polyethylene oxidepolymer in the active layer has an average molecular weight of about200K.

In certain embodiments, the placebo layer comprises polyethylene oxidepolymer having a molecular weight of about 900K and the active layercomprises polyethylene oxide polymer having a molecular weight of about200K.

In certain embodiments, the active pharmaceutical ingredient and thepolyethylene oxide polymer in the active layer are present in a ratio ofbetween about 20:80 and about 40:60.

In certain embodiments, the active layer further includes an osmogenselected from the group consisting of sodium chloride, potassiumchloride, potassium sulfate, lithium sulfate, sodium sulfate, lactoseand sucrose combination, lactose and dextrose combination, sucrose,dextrose, mannitol, dibasic sodium phosphate, or combinations thereof.

In certain embodiments, the osmogen in the active layer is sodiumchloride.

In certain embodiments, the active layer comprises the osmogen in anamount of between about 2 wt % and about 20 wt % of the active layer.

In certain embodiments, any of the placebo layer, the active layer, andthe push layer further comprise a binder, a stabilizer, and/or alubricant.

In certain embodiments, the high molecular weight polyethylene oxidepolymer in the push layer has a molecular weight of at least about 1M,about 2M, about 4M, about 5M, about 7M, or intermediate values thereof.

In certain embodiments, the high molecular weight polyethylene oxidepolymer in the push layer has a molecular weight of at least about 4M.

In certain embodiments, the osmogen in the push layer is selected fromthe group consisting of sodium chloride, potassium chloride, potassiumsulfate, lithium sulfate, sodium sulfate, lactose and sucrosecombination, lactose and dextrose combination, sucrose, dextrose,mannitol, dibasic sodium phosphate, or combinations thereof.

In certain embodiments, the osmogen is sodium chloride.

In certain embodiments, the osmogen in the push layer is present in anamount of between about 5 wt % and about 30 wt % of the push layer.

In certain embodiments, the stabilizer is succinic acid, butylatedhydroxytoluene, or a combination thereof.

The presently disclosed subject matter also provides an oralosmotic-controlled composition providing an immediate release of atherapeutically acceptable amount of a sedative and a delayed release ofa therapeutically acceptable amount of a stimulant, the compositioncomprising a multilayered core comprising the stimulant and an osmogen,a semipermeable membrane containing an orifice, over the core, and animmediate release layer, comprising the sedative, over the semipermeablemembrane. In certain embodiments, when the composition is placed in adissolution medium comprising 900 ml of aqueous solution of 0.01N HCl,at a pH of about 2.0, for up to 24 hours, the composition provides animmediate release of the sedative, followed by a lag time of at leastabout 6 hours during which the composition releases no more than 10% ofthe stimulant, followed by extended release of the stimulant for about10-16 hours, as measured in USP Apparatus II, at 37° C. and agitation at50 rpm. In certain embodiments, the composition provides a drug recoveryof at least about 90% at about 22 hours from the time of administrationinto the dissolution medium, and exhibits minimal variability in the lagtime with variations in pH, volume of the dissolution medium, and/or theviscosity of the dissolution medium.

In certain embodiments, the sedative is selected from the groupconsisting of clonidine, guanfacine, diphenhydramine, and melatonin.

In certain embodiments, the stimulant is methylphenidate hydrochlorideor mixed amphetamines.

In certain embodiments, the multilayered core comprises a placebo layer,an active layer, and a push layer, and the placebo layer issubstantially free of osmogen and disintegrant.

In certain embodiments, the placebo layer comprises at least one lowmolecular weight polyethylene oxide polymer and is substantially free ofosmogen and disintegrant.

In certain embodiments, the active layer comprises a stimulant and atleast one low molecular weight polyethylene oxide polymer.

In certain embodiments, the push layer comprises at least one highmolecular weight polyethylene oxide polymer and an osmogen.

In certain embodiments, the semipermeable membrane comprises apH-independent water-insoluble polymer and a pH-independent pore formerin a polymer to pore former ratio of between about 80:20 and about99.5:0.5.

In certain embodiments, the semipermeable membrane comprises apH-independent water-insoluble polymer and a pH-independent pore formerin a polymer to pore former ratio of between about 90:10 and about99.5:0.5.

In certain embodiments, the semipermeable membrane is applied with acoating weight gain of about 12.5 wt % of the multilayered core.

In certain embodiments, the pH-independent water-insoluble polymer inthe semipermeable membrane comprises polymers selected from the groupconsisting of cellulose acetate, cellulose acetate butyrate, cellulosetriacetate, and combinations thereof.

In certain embodiments, the pH-independent water-insoluble polymer iscellulose acetate.

In certain embodiments, the pore former is selected from the groupconsisting of polyethylene glycol, hydroxypropyl cellulose, polyvinylpyrolidone, polyvinyl acetate, mannitol, and methyl cellulose,poloxamer, triethyl citrate, triacetin, hydroxypropyl methylcellulose,glycerol, and combinations thereof.

In certain embodiments, the pore former is polyethylene glycol orpoloxamer.

In certain embodiments, the semipermeable membrane further comprises atleast one plasticizer selected from the group consisting of polyethyleneglycols, triethyl citrate, triacetin, diethyl tartrate, and combinationsthereof.

In certain embodiments, the water-insoluble polymer is cellulose acetateand the pore former is polyethylene glycol.

In certain embodiments, the cellulose acetate and polyethylene glycolare present in a ratio of about 95:5 or about 98:2.

In certain embodiments, the water-insoluble polymer is cellulose acetateand the pore former is poloxamer.

In certain embodiments, the cellulose acetate and poloxamer are presentin a ratio of between about 80:20 and about 99.5:0.5.

In certain embodiments, the delayed release comprises a delayed extendedrelease or a delayed chrono release.

In certain nonlimiting embodiments the active layer comprises animmediate release layer and an extended release layer to provide adelayed chrono release of the stimulant.

In certain embodiments, the layers in the multilayered core are arrangedin the following order: a placebo layer in fluid communication with theorifice in the semipermeable membrane, the active layer, and the pushlayer, wherein the push layer is facing away from the orifice.

In certain embodiments, the low molecular weight polyethylene oxidepolymer in the placebo layer has an average molecular weight of about100K, about 200K, about 300K, about 600K, about 900K, or intermediatevalues thereof.

In certain embodiments, the low molecular weight polyethylene oxidepolymer in the placebo layer has an average molecular weight of at leastabout 600K.

In certain embodiments, the low molecular weight polyethylene oxidepolymer in the placebo layer has an average molecular weight of about900K.

In certain embodiments, the low molecular weight polyethylene oxidepolymer in the active layer has an average molecular weight of about100K, about 200K, about 300K, about 600K, about 900K, or intermediatevalues thereof.

In certain embodiments, the low molecular weight polyethylene oxidepolymer in the active layer has an average molecular weight of about200K.

In certain embodiments, the placebo layer comprises polyethylene oxidepolymer having a molecular weight of about 900K and the active layercomprises polyethylene oxide polymer having a molecular weight of about200K.

In certain embodiments, the stimulant and the low molecular weightpolyethylene oxide polymer in the active layer are present in a ratio ofbetween about 20:80 and about 40:60.

In certain embodiments, the active layer further includes an osmogenselected from the group consisting of sodium chloride, potassiumchloride, potassium sulfate, lithium sulfate, sodium sulfate, lactoseand sucrose combination, lactose and dextrose combination, sucrose,dextrose, mannitol, dibasic sodium phosphate, or combinations thereof.

In certain embodiments, the osmogen in the active layer is sodiumchloride.

In certain embodiments, the active layer comprises the osmogen in anamount of between about 2 wt % and about 20 wt % of the active layer.

In certain embodiments, any of the placebo layer, the active layer, andthe push layer further comprises a binder, a stabilizer, and/or alubricant.

In certain embodiments, the high molecular weight polyethylene oxidepolymer in the push layer has an average molecular weight of at leastabout 1M, about 2M, about 4M, about 5M, about 7M, or any intermediatevalues thereof.

In certain embodiments, the high molecular weight polyethylene oxidepolymer in the push layer has an average molecular weight of at leastabout 4M.

In certain embodiments, the osmogen in the push layer is selected fromthe group consisting of sodium chloride, potassium chloride, potassiumsulfate, lithium sulfate, sodium sulfate, lactose and sucrosecombination, lactose and dextrose combination, sucrose, dextrose,mannitol, dibasic sodium phosphate, or combinations thereof.

In certain embodiments, the osmogen is sodium chloride.

In certain embodiments, the osmogen in the push layer is present in anamount of between about 5 wt % and about 30 wt % of the push layer.

In certain embodiments, the stabilizer is succinic acid, butylatedhydroxytoluene, or a combination thereof.

The presently disclosed subject matter also provides anosmotic-controlled oral pharmaceutical composition providing delayedrelease of a therapeutically effective amount of an activepharmaceutical ingredient, the composition comprising a multilayeredcore comprising the active pharmaceutical agent and an osmogen, and asemipermeable membrane, containing an orifice, over the core. In certainembodiments, the multilayered core comprises a placebo layer, an activelayer, and a push layer, the placebo layer is substantially free ofosmogen and disintegrant, and the composition exhibits minimalvariability in lag time when tested for dissolution in 900 ml of 0.01 NHCl, using USP Type II apparatus with a paddle speed of 50 rpm, or whentested for dissolution in 250 ml of 0.01 N HCl, using USP Type IIIapparatus with a speed of 25 dpm.

The presently disclosed subject matter additionally provides a methodfor treating ADHD in a subject, the method comprising orallyadministering to the subject an osmotic-controlled pharmaceuticalcomposition providing a delayed extended release dose of atherapeutically acceptable amount of methylphenidate hydrochloride. Incertain embodiments, the composition is administered to the subject,with or without food, before bedtime, and the delayed release dose ofmethylphenidate keeps the subject active and focused throughout the day,the composition comprises a multilayered core comprising the activepharmaceutical agent and an osmogen, and a semipermeable membrane,containing an orifice, over the core, the multilayered core comprises aplacebo layer, an active layer, and a push layer, and the placebo layeris substantially free of osmogen and disintegrant.

Furthermore, the presently disclosed subject matter provides a methodfor improving patient compliance and convenience during treatment ofADHD, the method comprising orally administering to a patient acomposition comprising a therapeutically acceptable amount of astimulant before bedtime to provide a delayed release dose of thestimulant that keeps the subject alert and focused during the day. Incertain embodiments, the composition delays the release of the stimulantto provide a lag time of at least about 6 hours, and during the lag timethe plasma concentration of the stimulant is less than about 10% of themaximum concentration (Cmax). In certain embodiments the compositioncomprises a multilayered core comprising the stimulant and an osmogen,and a semipermeable membrane, containing an orifice, over the core, themultilayered core comprises a placebo layer, an active layer, and a pushlayer, and the placebo layer is substantially free of osmogen anddisintegrant.

The foregoing has outlined broadly the features and technical advantagesof the present application in order that the detailed description thatfollows may be better understood. Additional features and advantages ofthe application will be described hereinafter which form the subject ofthe claims of the application. It should be appreciated by those skilledin the art that the conception and specific embodiment disclosed may bereadily utilized as a basis for modifying or designing other structuresfor carrying out the same purposes of the present application. It shouldalso be realized by those skilled in the art that such equivalentconstructions do not depart from the spirit and scope of the applicationas set forth in the appended claims. The novel features which arebelieved to be characteristic of the application, both as to itsorganization and method of operation, together with further objects andadvantages will be better understood from the following description.

5. BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 depicts a cross-section view of a four-layer osmotic dosage formcomprising an IR clonidine coating, a cellulose acetate coating,containing an orifice, below the clonidine IR coating, a placebo layerin fluid communication with the orifice, a delayed immediate releaselayer containing methylphenidate and placed below the placebo layer, adelayed extended release layer containing methylphenidate and placedbelow the delayed immediate release layer, and a push layer placed belowthe delayed extended release layer, the push layer being furthest fromthe orifice (i.e., facing away from the orifice).

FIG. 2 depicts a cross-section view of a three-layer osmotic dosage formcomprising a cellulose acetate coating containing an orifice, a placebolayer in fluid communication with the orifice, a delayed extendedrelease layer containing methylphenidate and placed below the placebolayer, and a push layer placed below the delayed extended release layerand facing away from the orifice.

FIG. 3 depicts a cross-section view of a three-layer osmotic dosage formcomprising an IR clonidine coating, a cellulose acetate coatingcontaining an orifice below the clonidine IR coating, a placebo layer influid communication with the orifice, a delayed extended release layercontaining methylphenidate and placed below the placebo layer, and apush layer placed below the delayed extended release layer and facingaway from the orifice.

FIG. 4 depicts a cross-section view of a three-layer osmotic dosage formcomprising an IR clonidine coating, a cellulose acetate coatingcontaining an orifice below the clonidine IR coating, a “placebo” layercontaining small amounts of a drug for IR and in fluid communicationwith the orifice, a delayed extended release layer containingmethylphenidate and placed below the placebo layer, and a push layerplaced below the delayed extended release layer and facing away from theorifice.

FIG. 5 depicts a cross-section view of a three-layer osmotic dosage formcomprising an IR clonidine coating, a seal coating below the IRclonidine coat, a clonidine ER coating below the seal coating, acellulose acetate coating containing an orifice below the ER clonidinecoating, a “placebo” layer in fluid communication with the orifice, adelayed extended release layer containing methylphenidate and placedbelow the placebo layer, and a push layer placed below the delayedextended release layer and facing away from the orifice.

FIG. 6 depicts a cross-section view of a five-layer osmotic dosage formcomprising an IR coating containing a drug for IR, a cellulose acetatecoating containing an orifice below the IR coating, a first placebolayer in fluid communication with the orifice, a first IR drug layerbelow the first placebo layer, a second placebo layer below the first IRdrug layer, a second IR drug layer below the second placebo layer, and apush layer placed below the second IR drug layer and facing away fromthe orifice.

FIG. 7 shows the effect of the amount of POLYOX® in the placebo layer onthe dissolution rate of the tablet in about 900 ml of about 0.01N HCl.Tablet 20 contained about 150 mg/dose of POLYOX® WSR 1105, Tablet 21contained about 75 mg/dose of POLYOX® WSR 1105 in the placebo layer.Percent dissolved is plotted over time (hours).

FIG. 8 compares dissolution profiles in about 900 ml of about 0.01N HClof tablets containing POLYOX® 1105 and POLYOX® 205 in the placebo layer.Tablet 20 contained POLYOX® WSR 1105, Tablet 22 contained POLYOX® 205 inthe placebo layer. Percent dissolved is plotted over time (hours).

FIG. 9 compares dissolution profiles in about 900 ml of about 0.01N HClof tablets containing active layers with drug to polymer ratio of about20:80 (Tablet 23) and drug to polymer ratio of about 28:72 (Tablet 24).Percent dissolved is plotted over time (hours). The Figure demonstratesthat lag time is reduced with increasing drug to polymer ratio.

FIG. 10 compares dissolution profile in about 900 ml of about 0.01N HClof tablets containing sodium chloride in the active layer (Tablet 25)and tablets containing no sodium chloride in the active layer (Table26). Percent dissolved is plotted over time (hours). The Figuredemonstrates that presence of sodium chloride in the active layerimproves drug recovery by about 5%, compared to tablets without sodiumchloride in the active layer.

FIG. 11 shows the effect of sodium chloride in the push layer on lagtime and drug recovery. The Figure compares dissolution profiles inabout 900 ml of about 0.01N HCl of tablets containing about 0 wt %(Tablet 29), about 10 wt % (Tablet 24), about 18 wt %, (Tablet 28) andabout 25 wt % (Tablet 27) of sodium chloride in push layer. Percentdissolved is plotted over time (hours). The Figure demonstrates thatpresence of sodium chloride in push layer improves release rate and drugrecovery, when compared with compositions without any sodium chloride inpush layer.

FIG. 12 shows the effect of the cellulose acetate to polyethylene glycolratio in the semipermeable membrane on lag time and drug recovery of thetablets with a 15% coating weight gain. The Figure compares dissolutionprofiles in about 900 ml of about 0.01N HCl of tablets containingOPADRY® CA with CA:PEG ratio of about 95:5 (Tablet 30) and OPADRY® CAwith CA:PEG ratio of about 98:2 (Tablet 31). Percent dissolved isplotted over time (hours). The Figure demonstrates that the lag timeincreases with increasing amount of cellulose acetate in the membrane.

FIG. 13 shows the effect of the presence of sodium chloride in theactive layer and the effect of the coating weight gain/coating level ofthe semipermeable membrane on lag time and drug recovery. The Figurecompares dissolution profiles in about 900 ml of about 0.01N HCl ofTablets 32, 33, and 34. Percent dissolved is plotted over time (hours).The Figure demonstrates that lag time increases with increasing coatinglevel of the semipermeable membrane. The Figure further demonstratesthat presence of sodium chloride in active layer improves drug recovery.

FIG. 14 compares the drug recovery between tablets containing differentamounts of sodium chloride in the active layer and/or different gradesof POLYOX® in the placebo layer. The Figure compares dissolutionprofiles in about 900 ml of about 0.01N HCl of tablets containing about20 mg/dose of sodium chloride in the active layer and POLYOX® 205 in theplacebo layer (Tablet 35), about 10 mg/dose of sodium chloride in theactive layer and POLYOX® 205 in the placebo layer (Tablet 36), and about10 mg/dose of sodium chloride in the active layer and POLYOX® 1105 inthe placebo layer (Tablet 37). Percent dissolved is plotted over time(hours). The Figure demonstrates that drug recovery increases withincreasing the amount of sodium chloride in active layer and reducingthe molecular weight of POLYOX® in placebo layer.

FIG. 15 shows the effect of the amount of POLYOXR in the push layer onlag time. The Figure compares dissolution profiles in about 900 ml ofabout 0.01N HCl of tablets containing various amounts of POLYOX® (Tablet38, and Tablet 39). Percent dissolved is plotted over time (hours). TheFigure demonstrates that lag time decreases with increasing the amountof POLYOX® in push layer.

FIG. 16 compares the lag time and dissolution profiles of a compositionof the disclosure (Tablet 40) in about 900 ml of about 0.01N HCl, pH 4.5acetate buffer, and pH 6.8 phosphate buffer. Percent dissolved isplotted over time (hours). The Figure demonstrates that lag time isindependent of the pH of the dissolution medium.

FIG. 17 compares dissolution profiles in about 900 ml of about 0.01N HClof tablets with a drug to polymer weight ratio of about 40:60 in thepush layer (Tablet 41 and Tablet 42). Percent dissolved is plotted overtime (hours). The Figure demonstrates that compositions containing adrug to polymer weight ratio of about 40:60 do not show any change inlag time, and improve drug recovery, with increasing amount of pushlayer.

FIG. 18 dissolution profiles in about 900 ml of about 0.01N HCl oftablets with about 12.5% and about 15% coating weight gain and varyingamounts of POLYOX® 1105 in the placebo layer (Tablet 43 and Tablet 44).Percent dissolved is plotted over time (hours). FIG. 18 demonstratesthat lag time increases and drug recovery decreases with an increase inthe coating weight gain from about 12.5% to about 15%.

FIG. 19 compares the dissolution rates of a composition of thedisclosure (Tablet 45) at pH 2 (about 0.01 N HCl), pH 4.5 acetatebuffer, and pH 6.8 phosphate buffer. Percent dissolved is plotted overtime (hours).

FIG. 20 provides the dissolution rates of a composition of thedisclosure (Tablet 45) in dissolution mediums with differentviscosities, e.g., with and without HPMC. Percent dissolved is plottedover time (hours).

FIG. 21 compares the dissolution profiles in about 900 ml of about 0.01NHCl of tablets of a composition of the disclosure (Tablet 45), with adrug to polymer weight ratio of about 40:60, using USP Apparatus II andUSP Apparatus III. Percent dissolved is plotted over time (hours).

FIG. 22 compares the dissolution profiles in about 900 ml of about 0.01NHCl of tablets containing about 0% sodium chloride (Tablet 44), about 5%sodium chloride

(Tablet 46), and about 10% sodium chloride (Tablet 47) in the placebolayer. Percent dissolved is plotted over time (hours).

FIG. 23 compares the dissolution profiles in about 900 ml of about 0.01NHCl of tablets containing POLYOX® 1105 (Tablet 44), POLYOX® 750 (Tablet48), POLYOX® N80 (Tablet 49), in the placebo layer. Percent dissolved isplotted over time (hours).

FIG. 24 compares the dissolution profiles in about 900 ml of about 0.01NHCl of tablets containing POLYOX® 303 (Tablet 44), POLYOX® 301 (Tablet50), POLYOX® coagulant (Tablet 51) in the push layer. Percent dissolvedis plotted over time (hours).

FIG. 25 compares dissolution profiles in about 900 ml of about 0.01N HClof Tablet 52 and Tablet 53. Percent dissolved is plotted over time(hours). The Figure demonstrates that addition of a super-disintegrantand sodium chloride in the placebo layer reduces the drug recoverywithout substantially affecting lag time.

6. DETAILED DESCRIPTION

6.1. Definitions

The terms used in this specification generally have their ordinarymeanings in the art, within the context of this subject matter and inthe specific context where each term is used. Certain terms are definedbelow to provide additional guidance in describing the compositions andmethods of the disclosed subject matter and how to make and use them.

The terminology used in the present disclosure is for the purpose ofdescribing particular embodiments only and is not intended to belimiting.

As used herein, the use of the word “a” or “an” when used in conjunctionwith the term “comprising” in the claims and/or when used in thespecification can mean “one,” but it is also consistent with the meaningof “one or more,” “at least one,” and “one or more than one.” Stillfurther, the terms “having,” “including,” “containing,” and “comprising”are interchangeable, and one of skill in the art is cognizant that theseterms are open-ended terms.

As used herein, “and/or” refers to and encompasses any and all possiblecombinations of one or more of the associated listed items.

The term “about” or “approximately” means within an acceptable errorrange for the particular value as determined by one of ordinary skill inthe art, which will depend in part on how the value is measured ordetermined, i.e., the limitations of the measurement system. Forexample, “about” can mean within 3 or more than 3 standard deviations,per the practice in the art. Alternatively, “about” can mean a range ofup to 20%, up to 15%, up to 10%, up to 5%, up to 1%, up to 0.5%, or evenup to 0.1% of a given value. Unless otherwise defined, all terms,including technical and scientific terms used in the description, havethe same meaning as commonly understood by one of ordinary skill in theart to which this disclosure belongs. As used herein, “about” will beunderstood by persons of ordinary skill in the art and will vary to someextent on the context in which it is used. If there are uses of the termwhich are not clear to person of ordinary skill in the art given thecontext in which it is used, “about” will mean up to ±10% of theparticular term.

As used herein, a “therapeutically effective,” “therapeutic,” or“therapeutically acceptable” amount refers to an amount that will elicita therapeutically useful response in a subject and includes anadditional amount or overage of active ingredient deemed necessary inthe formulation to provide the desired amount upon administration. Thetherapeutically useful response can provide some alleviation,mitigation, and/or decrease in at least one clinical symptom in thesubject. Those skilled in the art will appreciate that thetherapeutically useful response need not be complete or curative, aslong as some benefit is provided to the subject. In some embodiments,the subject is a mammal. In some embodiments, the subject is a human.

As used herein, the term “drug recovery” refers to percentage of thetotal amount of drug present in the dosage form that is released in adissolution medium. The term “complete drug recovery” refers to releaseof about 90% to about 105% of the drug present in the dosage form.

The term “bioavailability” refers to the fraction of an administereddose of unchanged drug that reaches the systemic circulation.

As used herein, the terms “treatment,” “treat,” and “treating” refer toreversing, alleviating, delaying the onset of, and/or inhibiting theprogress of a disease or disorder as described herein. In someembodiments, treatment can be administered after one or more symptomshave developed. In other embodiments, treatment can be administered inthe absence of symptoms. For example, treatment can be administered to asusceptible individual prior to the onset of symptoms (e.g., in light ofa history of symptoms and/or in light of genetic or other susceptibilityfactors). Treatment can also be continued after symptoms have resolved,for example to prevent or delay their recurrence.

The term “chrono release” refers to drug release in a sequential orderof time. In particular, the term “chrono release” means timed orprogrammed release of one or more drugs at a rhythm that matches thehuman circadian rhythm of a condition's symptoms and/or of theindividual being treated in the application of the therapy to optimizethe therapeutic outcome and minimize side effects. In certainembodiments, the term “chrono release” comprises immediate release of adrug followed by an extended release of the same or different drug.

The term “pulsatile release” means rapid release of discrete portions ofdrug in pulses that are separated by a well-defined lag time(s).

The term “lag time” means the time for which release of a drug isdelayed from the time of administration/ingestion of the composition.Not more than about 10% of the maximum plasma concentration (Cmax) ofthe drug is released during the lag time.

The term “release rate” refers to the quantity of drug released per unittime, e.g., mg of drug released per hour (mg/hour), from a dosage form.Drug release rates are calculated under in vitro dosage form dissolutiontesting conditions known in the art.

The term “delayed release” means release of a discrete portion(s) of adrug at a time(s) other than immediately after administration/ingestion.

The term “immediate release” means substantially complete release of adrug within a time period of about 1 hour or less, preferably within 30minutes or less, post-administration.

The term “immediate release drug layer” means an immediate releasecoating layer comprising a drug and at least one pharmaceuticallyacceptable carrier. The immediate release drug layer dissolves rapidlyupon administration and provides an immediate release dose of the drug.

The term “controlled release” means drug release that is controlled toalter the timing and/or rate of release of the drug substance from thatof a conventional immediate release dosage form. The controlled releasedosage forms of the disclosure can include modified release dosage formsproviding delayed release (DR), extended release (ER), target release(TR), pulsatile release, chrono release, or any combination thereof, ofdrug substance.

The term “extended release” refers to modified release dosage forms orcompositions that are formulated to allow the drug to be available overan extended period of time after administration, thereby allowing areduction in dosing frequency, as compared to a drug presented as animmediate release dosage form.

The term “solubility” is defined in terms of ability to dissolve inwater. The term “highly soluble” includes drugs with a solubility ofgreater than 100 mg/ml of water; the term “moderately soluble” includesdrugs with a solubility of between 100 mg/ml and 1 mg/ml of water; theterm “sparingly soluble” includes drugs with a solubility of between 1mg/ml and 0.1 mg/ml of water.; and the term “insoluble” includes drugswith a solubility of less than 0.1 mg/ml of water.

The term “osmosis” is defined as spontaneous movement of a solvent froma solution of lower solute concentration to a solute or a solution ofhigher solute concentration through a semipermeable membrane, whereinthe membrane is permeable to the solvent and impermeable to the solute.

The term “osmotic pressure” is defined as pressure exerted on a highersolvent concentration side of the dosage form to inhibit solvent flowinto the dosage form.

The term “substantially free” is defined as excluding any functional(e.g., noncontaminating) amount, which refers to any amount thatcontributes or has an effect on release profile or lag time of thecomposition.

The term “semipermeable membrane” is defined as a polymeric membrane orfilm that is substantially impermeable to the passage of solutes, e.g.,a drug and other excipients, and substantially permeable to passage offluids (e.g., water). As used herein, the terms functional coat andsemipermeable membrane are used interchangeably.

The term “coating weight gain” refers to weight gain due to coating,with respect to the uncoated tablet. For example, a coating weight gainof about 15% refers to an about 15 wt % increase in tablet weight duringcoating with respect to the uncoated tablet weight.

The terms “pore former” and the like, as used herein, refer towater-soluble polymers and/or water-soluble small molecules that willform pores or channels (i.e., behave as a channeling agent) in asemipermeable membrane to improve permeability of the membrane.

The terms “shear” and “shear effect,” as used interchangeably herein,refer to peristaltic waves, particularly under fed conditions, movingfrom the mid-corpus of the stomach to the pylorus. Dissolution ofcompositions using USP Apparatus II (Sinkers) with agitation at 50 rpmat 37° C., and using USP Apparatus III (Biodis) with agitation at 25 dpmat 37° C., mimics the effects of stomach shear on the dissolution rateof the composition.

The term “orifice” includes an opening/exit means in coatings, e.g., inthe semipermeable membrane coat, the seal coat, and/or the overcoat, ofan osmotic-controlled composition, to provide fluid communication with,e.g., the placebo layer. The appropriate opening can be formed by anymeans, e.g., by manual or laser drilling of the membrane.

The term “osmotic agent” includes swellable hydrophilic polymers, andosmogens/ionic compounds consisting of inorganic salts.

The term “patient” or “subject,” as used herein, refers to a human ornonhuman mammal that is in need or may be in need to receive an osmoticdosage form of the present disclosure.

The terms “drug,” “active agent,” “active ingredient,” and “activepharmaceutical ingredient/agent” are used interchangeably herein andinclude compounds that will elicit a therapeutically useful response ina subject; such terms include all pharmaceutically acceptable salts,esters, and functionally equivalent chemical compounds.

As used herein, the terms “methylphenidate” and “methylphenidatehydrochloride” are used interchangeably herein. The term“methylphenidate” includes all pharmaceutically acceptable salts,esters, and functionally equivalent chemical compounds.

As used herein, the terms “clonidine” and “clonidine hydrochloride” areused interchangeably herein. The term “clonidine” includes allpharmaceutically acceptable salts, esters, and functionally equivalentchemical compounds.

6.2. Multi-layer Osmotic Tablet

The present disclosure provides programmable osmotic-controlled oralcompositions comprising a multilayer core (e.g., a multilayer tabletcore) comprising a drug, wherein the core is coated with a semipermeablemembrane comprising an orifice and, optionally, an immediate releasecoating comprising a drug for immediate release, over the semipermeablemembrane. The multilayered tablet core comprises a pull layer containingthe drug and a push layer. The pull layer comprises at least two layers:a placebo layer, in fluid communication with the orifice, for providinga desired lag time for drug release; and an active layer containing thedrug and providing a delayed controlled release of the drug. In certainembodiments, the tablets are vertically compressed producing acapsule-shaped product. In certain embodiments, such shape ensurescomplete extrusion of drug from the orifice.

For any of the dosage forms, compositions, and methods of thedisclosure, the push layer is present in an amount that expands involume to a size that pushes the entire drug solution or suspension inthe pull layer, e.g., the placebo and active layers, out of the tabletthrough a delivery port/orifice, providing, e.g., complete drug recoveryfrom the dosage form. In certain embodiments, the pull layer and thepush layer are present in a ratio of about 2:1, about 1.5:1, about 1:1,or any intermediate values therein. In certain embodiments, the weightof push layer is about 33% or more of the total weight of the trilayercore. In certain embodiments, the weight of the placebo layer or theactive layer is about 33% or more of the total weight of the trilayercore. In certain embodiments, the weight of the placebo layer or theactive layer is half or more of the total weight of the trilayer core.In certain embodiments, the relative weight percentages (relative to thetotal weight of the trilayer core) of the placebo layer, the activelayer, and the push layer can be between about 25 wt % to about 40 wt %,between about 25 wt % to about 40 wt %, and between about 20 wt % toabout 50 wt %, respectively. Furthermore, each of the layers, i.e., theactive layer, the placebo layer, and the push layer, can comprisepolyethylene oxide (e.g., POLYOX®).

In certain embodiments, the placebo layer and the push layer are free ofany active pharmaceutical ingredient. In certain embodiments, the activepharmaceutical ingredient contained in the active layer does notleach/migrate into the placebo layer or the push layer during the invitro drug release test. In certain embodiments, during the dissolutionof the placebo layer, less that about 5 wt %, less than about 4 wt %,less than about 3 wt %, less than about 2 wt %, or less than about lwt %of the total dose of the active pharmaceutical ingredient is releasedwithin about 6 hours from the time of administration of the dosage form.Similarly, less that about 5 wt %, less than about 4 wt %, less thanabout 3 wt %, less than about 2 wt %, or less than about 1 wt % of thetotal dose of the active pharmaceutical ingredient is released betweenabout 2 hours and about 10 hours, between about 2 hours and about 8hours, between about 2 hours and about 7 hours, or between about 2 hoursand about 6 hours following administration of the dosage form.

6.2.1. Placebo Layer: In certain embodiments, the placebo layer/placebolayer blend, is located adjacent to and in fluid communication with theorifice in the semipermeable membrane. In certain embodiments, theplacebo layer blend comprises a low molecular weight swellablehydrophilic polymer, e.g., low molecular weight POLYOX®, a binder, alubricant, and a glidant. In certain embodiments, the placebo layerfurther comprises a color pigment. In certain embodiments, the placebolayer blend is substantially free of any active pharmaceuticalingredient. In certain embodiments, the placebo layer contains less thanabout 2 wt %, less than about 1 wt %, less than about 0.5 wt %, lessthan about 0.2 wt %, less than about 0.1 wt %, or less than about 0.01wt % of the active pharmaceutical ingredient.

In certain embodiments, the placebo layer blend further includes astabilizer to prevent degradation of polyethylene oxide polymer, e.g.,POLYOX®. In certain embodiments, the placebo layer blend includesgranules containing POLYOX®, binder, stabilizer, and color pigment. Incertain embodiments, glidant and lubricant are present as extragranularexcipients in the placebo layer.

In certain embodiments, the placebo layer includes low molecular weightpolyethylene oxide polymer, e.g., low molecular weight POLYOX®. Incertain embodiments, the molecular weight/grade of the low molecularweight POLYOX® in the placebo layer affects drug recovery, lag time,and/or release profile, of the composition. In certain embodiments, thelow molecular weight POLYOX® has an average molecular weight of <about1M, e.g., about 100K (POLYOX® N-10), about 200K (POLYOX® N-80), about300K (POLYOXN-750), about 600K (POLYOXN- 205), about 900K(POLYOXN-1105), or intermediate values thereof. In certain embodiments,the viscosity of the placebo layer can be adjusted to provide a desiredand consistent lag time. In certain embodiments, the viscosity of theplacebo layer depends upon the average molecular weight of the POLYOX®present in the placebo layer. In certain embodiments, the placebo layercontains POLYOX® 205 or POLYOX® 1105. In certain embodiments, theplacebo layer contains POLYOX® 1105. In certain embodiments, the lowmolecular weight POLYOX® is present in an amount of about 50 wt % toabout 99 wt % of the placebo layer. In certain embodiments, the lowmolecular weight POLYOX® is present in an amount of about 50 wt %, about55 wt %, about 60 wt %, about 65 wt %, about 70 wt %, about 75 wt %,about 80 wt %, about 81 wt %, about 82 wt %, about 83 wt %, about 84 wt%, about 85 wt %, about 86 wt %, about 87 wt %, about 88 wt %, about 89wt %, about 90 wt %, about 91 wt %, about 92 wt %, about 93 wt %, about94 wt %, about 95 wt %, about 96 wt %, about 97 wt %, about 98 wt %,about 99 wt %, or any intermediate values therein, of the placebo layer.

In certain embodiments, the placebo layer comprises binders includingpovidone, hypromellose, starch, acacia, gellan gum, low viscosityhydroxypropyl cellulose, methylcellulose, sodium methylcellulose,polyvinyl alcohol, polyvinyl acetates (e.g., KOLLICOAT® SR),polyethylene oxide (e.g., POLYOX®), polyethylene glycol, alginates,pegylated polyvinyl alcohol, or any combination thereof. In certainembodiments, the binder is povidone. In certain embodiments, the bindersare present in an amount of about 0.5 wt % to about 20 wt % of theplacebo layer. In certain embodiments, the binders are present in anamount of about 0.5 wt %, about 0.6 wt %, about 0.7 wt %, about 0.8 wt%, about 0.9 wt %, about 1 wt %, about 2 wt %, about 3 wt %, about 4vsrt%, about 5 wt %, about 6 wt %, about 7 vsrt%, about 8 wt %, about 9vsrt%, about 10 wt %, about 11 wt %, about 12 wt %, about 13 wt %, about14 wt %, about 15 wt %, about 16 wt %, about 17 wt %, about 18 wt %,about 19 wt %, about 20 wt %, or any intermediates values therein, ofthe placebo layer.

In certain embodiments, the placebo layer includes at least onestabilizer to prevent degradation of POLYOX®. In certain embodiments,the stabilizer comprises antioxidants including ascorbic acid and itssalts, tocopherols, sulfite salts such as sodium metabisulfite or sodiumsulfite, sodium sulfide, butylated hydroxyanisole (BHA), butylatedhydroxytoluene (BHT), ascorbyl palmitate, propyl gallate, or anycombination thereof. In certain embodiments, the antioxidant is BHT. Incertain embodiments, the stabilizer is present in an amount of about0.01 wt % to about 0.5 wt % of the placebo layer. In certainembodiments, the stabilizer is present in an amount of about 0.01 wt %,about 0.02 wt %, about 0.03 wt %, about 0.04 wt %, about 0.05 wt %,about 0.06 wt %, about 0.07 wt %, about 0.08 wt %, about 0.09 wt %,about 0.10 wt %, about 0.2 wt %, about 0.3 wt %, about 0.4 wt %, about0.5 wt %, or any intermediate values therein, of the placebo layer.

In certain embodiments, the placebo layer comprises at least onelubricant including magnesium stearate, glyceryl monostearates, palmiticacid, talc, carnauba wax, calcium stearate sodium, sodium or magnesiumlauryl sulfate, calcium soaps, zinc stearate, polyoxyethylenemonostearates, calcium silicate, silicon dioxide, hydrogenated vegetableoils and fats, stearic acid, and any combination thereof. In certainembodiments, the lubricant is magnesium stearate. In certainembodiments, the lubricant is present in an amount of about 0.5 wt % toabout 2 wt % of the placebo layer. In certain embodiments, the lubricantis present in an amount of about 0.5 wt %, about 0.6 wt %, about 0.7 wt%, about 0.8 wt %, about 0.9 wt %, about 1.0 wt %, about 1.1 wt %, about1.2 wt %, about 1.3 wt %, about 1.4 wt %, about 1.5 wt %, about 1.6 wt%, about 1.7 wt %, about 1.8 wt %, about 1.9 wt° /0, about 2.0 wt %, orany intermediate values therein, of the placebo layer.

In certain embodiments, the placebo layer comprises at least oneglidant, including talc, colloidal silicon dioxide, magnesiumtrisilicate, powdered cellulose, starch, tribasic calcium phosphate, orany combinations thereof. In certain embodiments, the glidant iscolloidal silicon dioxide. In certain embodiments, the glidant ispresent in an amount of about 0.1 wt % to about 5 wt % of the placebolayer. In certain embodiments, the glidant is present in an amount ofabout 0.1 wt %, about 0.2 wt %, about 0.3 wt %, about 0.4 wt %, about0.5 wt %, about 0.6 wt %, about 0.7 wt %, about 0.8 wt %, about 0.9 wt%, about 1 wt %, about 2 wt %, about 3 wt %, about 4 wt %, about 5 wt %,or any intermediate valued therein, of the placebo layer.

In certain embodiments, the placebo layer includes at least one colorpigment. In certain embodiments, the color pigment in the placebo layeris useful for distinguishing the placebo layer from the active layer. Incertain embodiments, the color pigment comprises iron oxide orlake-based colors. In certain embodiments, the pigment is a lake-basedcolor. In certain embodiments, the pigment is an iron oxide pigment,e.g., oxide pigment red or oxide pigment black. In certain embodiments,the pigment is present in an amount of about 0.01 wt % to about 0.5 wt %of the placebo layer.

In certain embodiments, the placebo layer is free of functionalexcipients such as osmogens, any disintegrants or water-entrainingagents, and glidants such as SYLLOID® 244 FP. It is surprisinglyobserved that the programmable osmotic-controlled oral compositions ofthe disclosure provide a precise lag time without the presence of anyosmogen and/or water-entraining agent to imbibe water, and/or anydisintegrants/wetting agents.

6.2.2. Active Layer: In certain embodiments, the active layer is locatedbetween (and adjacent to) and in contact with the placebo layer and thepush layer. In certain embodiments, the active layer/active layer blendincludes an active agent, a swellable hydrophilic polymer, a binder, anosmogen, and a lubricant. In certain embodiments, the activelayer/active layer blend further includes a glidant and/or a stabilizer.In certain embodiments, active layer blend includes granules containingan active agent, a swellable hydrophilic polymer, a binder, an osmogen,a stabilizer, and a color pigment. In certain embodiments, glidant andlubricant are present as extragranular excipients in the active layerblend. In certain embodiments, the swellable hydrophilic polymerscomprise low molecular weight hydrophilic polymers. In certainembodiments, the low molecular weight hydrophilic polymer is a swellablewater-entraining polymer required to hydrate the active layer andpartially dissolve or suspend drug particles. In certain embodiments,the low molecular weight hydrophilic polymers include polyethyleneoxide, carbopols, polyacrylamides, acrylate polymer polysaccharidecomposed of condensed glucose units, crospovidone, carboxymethylcellulose, and poly(alkalicarboxymethylcellulose), Methocel™ K100LVCR(methylcellulose and hydroxypropyl methyl cellulose), and anycombinations thereof. In certain embodiments, the low molecular weighthydrophilic polymers in the active layer comprise low molecular weightpolyethylene oxide polymers (e.g., POLYOX®).

In certain embodiments, drug to POLYOX® ratio, in the active layer,affects the lag time, release rate, and drug recovery of thecomposition. In certain embodiments, release rate and drug recovery fromthe composition increases with increasing the drug to POLYOX® ratio. Incertain embodiments, lag time decreases with increasing drug to POLYOX®ratio. In certain embodiments, the ratio of the drug and POLYOX® isbetween about 10:90 and about 90:10. In certain embodiments, the ratioof the drug and POLYOX® is about 10:90, about 20:80, about 30:70, about40:60, about 50:50, about 60:40, about 70:30, about 80:20, about 90:10,or intermediate values therein.

In certain embodiments, the grade of the polyethylene oxide polymer, andthe drug to polymer ratio in the active layer, affects drug recovery,lag time, and/or release profile, of the composition. In certainembodiments, the low molecular weight POLYOX® has an average molecularweight of <1M, e.g., about 100K (POLYOX® N-10), about 200K (POLYOX®N-80), about 300K (POLYOX™N-750), about 600K (POLYOX™N-205), about 900K(POLYOX™N-1105), or intermediate values thereof. In certain embodiments,the average molecular weight of POLYOX® is about 200K. In certainembodiments, the viscosity of the active layer is adjusted to provide adesired and consistent release profile. In certain embodiments, theviscosity of active layer depends upon the average molecularweight/grade of the POLYOX® present in the active layer. In certainembodiments, the active layer contains POLYOX®N-80 (200K). In certainembodiments, the low molecular weight POLYOX® is present in an amount ofabout 50 wt % to about 80 wt % of the active layer. In certainembodiments, the low molecular weight POLYOX® is present in an amount ofabout 50 wt %, about 55 wt %, about 60 wt %, about 65 wt %, about 70 wt%, about 71 wt %, about 72 wt %, about 73 wt %, about 74 wt %, about 75wt %, about 76 wt %, about 77 wt %, about 78 wt %, about 79 wt %, about80 wt %, or intermediate values therein, of the placebo layer.

In certain embodiments, the active layer further includes low viscosityhypromellose or hypromellose acetate succinate as a wetting agent toenhance wettability of drugs with low aqueous solubility. In certainembodiments, the low viscosity hypromellose or povidone are used asbinders, and stearic acid is used as a lubricant.

In certain embodiments, the active layer comprises binders includingpovidone, hypromellose, starch, acacia, gellan gum, low viscosityhydroxypropyl cellulose, methylcellulose, sodium methylcellulose,polyvinyl alcohol, polyvinyl acetates (e.g., KOLLICOAT® SR),polyethylene oxide (e.g., POLYOX®), polyethylene glycol, alginates,pegylated polyvinyl alcohol, or any combination thereof. In certainembodiments, the binder is povidone. In certain embodiments, the bindersare present in an amount of about 0.5 wt % to about 20 wt % of theactive layer. In certain embodiments, the binders are present in anamount of about 0.5 wt %, about 0.6 wt %, about 0.7 wt %, about 0.8 wt%, about 0.9 wt %, about 1 wt %, about 2 wt %, about 3 wt %, about 4 wt%, about 5 wt %, about 6 wt %, about 7 wt %, about 8 wt %, about 9 wt %,about 10 wt %, about 11 wt %, about 12 wt %, about 13 wt %, about 14 wt%, about 15 wt %, about 16 wt %, about 17 wt %, about 18 wt %, about 19wt %, about 20 wt %, or any intermediates values therein, of the activelayer.

In certain embodiments, the active layer comprises at least one osmogen.In certain embodiments, the osmogen includes ionic compounds ofinorganic salts that provide a concentration differential for osmoticflow of liquid into the composition. In certain embodiments, the osmogencomprises an ionic compound including sodium chloride, potassiumchloride, potassium sulfate, lithium sulfate, sodium sulfate, a lactoseand sucrose combination, a lactose and dextrose combination, sucrose,dextrose, mannitol, dibasic sodium phosphate, and any combinationthereof. In certain embodiments, the osmogen is sodium chloride. Incertain embodiments, the osmogen is present in an amount of about 2 wt %to about 20 wt % of the active layer. In certain embodiments, theosmogen is present in an amount of about 2 wt %, about 3 wt %, about 4wt %, about 5 wt %, about 6 wt %, about 7 wt %, about 8 wt %, about 9 wt%, about 10 wt %, about 15 wt %, about 20 wt %, or any intermediatevalues therein, of the active layer.

In certain embodiments, the active layer includes at least onestabilizer to prevent degradation of POLYOX®. In certain embodiments,the stabilizer comprises an antioxidant including one or more ofascorbic acid and its salts, tocopherols, sulfite salts such as sodiummetabisulfite or sodium sulfite, sodium sulfide, butylatedhydroxyanisole (BHA), butylated hydroxytoluene (BHT), ascorbylpalmitate, and propyl gallate. In certain embodiments, the antioxidantis BHT. In certain embodiments, the stabilizer is present in an amountof about 0.01 wt % to about 0.5 wt % of the active layer. In certainembodiments, the stabilizer is present in an amount of about 0.01 wt %,about 0.02 wt %, about 0.03 wt %, about 0.04 wt %, about 0.05 wt %,about 0.06 wt %, about 0.07 wt %, about 0.08 wt %, about 0.09 wt %,about 0.1 wt %, about 0.2 wt %, about 0.3 wt %, about 0.4 wt %, about0.5 wt %, or any intermediate values therein, of the active layer.

In certain embodiments, the active layer further includes surfactants tomodulate the solubility of the active agent. In certain embodiments, thesurfactant comprises one or more of esters of fatty acids; sorbitanfatty acid esters ethoxylated with from about 2 to about 30 moles ofethylene oxide; polyethylene glycol fatty acid esters; polyethyleneglycol esters and polyethylene glycol ethers; and polyethoxylatedcarboxylic acids, PEG-7 hydrogenated castor oil, and PEG-30dipolyhydroxystearate; block copolymers based on ethylene oxide andpropylene oxide; dioctyl sodium sulfosuccinate (docusate sodium); sodiumlauryl sulfate; PEG-32 glyceryl laurate; PEG-32 glycerylpalmitostearate; PEG-8 glyceryl caprylate/caprate; PEG-6 glycerylcaprylate/caprate; macrogol 15 hydroxystearate; polyoxyethylene 20sorbitan monolaurate (polysorbate 20); polyoxyethylene 20 sorbitanmonooleate (polysorbate 80); sorbitan monolaurate; sorbitan monooleate;and polyoxyl 40 stearate.

In certain embodiments, active layer can comprise a superdisintegrantincluding carmellose calcium, carboxymethylstarch sodium, croscarmellosesodium, crospovidone (crosslinked homopolymer of N-vinyl-2-pyrrolidone), low-substituted hydroxypropyl celluloses, sodium starchglycolate, colloidal silicon dioxide, alginic acid and alginates,acrylic acid derivatives, and various starches, or any combinationsthereof.

In certain embodiments, the active layer comprises lubricants includingmagnesium stearate, glyceryl monostearates, palmitic acid, talc,carnauba wax, calcium stearate sodium, sodium or magnesium laurylsulfate, calcium soaps, zinc stearate, polyoxyethylene monostearates,calcium silicate, silicon dioxide, hydrogenated vegetable oils and fats,stearic acid, or any combination thereof. In certain embodiments, thelubricant is magnesium stearate. In certain embodiments, the lubricantis present in an amount of about 0.01 wt % to about 2 wt % of the activelayer. In certain embodiments, the lubricant is present in an amount ofabout 0.01 wt %, about 0.02 wt %, about 0.03 wt %, about 0.04 wt %,about 0.05 wt %, about 0.1 wt %, about 0.2 wt %, about 0.3 wt %,about0.4 wt %,about 0.5 wt %, about 0.6 wt %, about 0.7 wt %, about 0.8 wt %,about 0.9 wt %, about 1.0 wt %, about 1.1 wt %, about 1.2 wt %, about1.3 wt %, about 1.4 wt %, about 1.5 wt %, about 1.6 wt %, about 1.7 wt%, about 1.8 wt %, about 1.9 wt %, about 2.0 wt %, or any intermediatevalues therein, of the active layer.

In certain embodiments, the active layer comprises glidants includingtalc, colloidal silicon dioxide, magnesium trisilicate, powderedcellulose, starch, tribasic calcium phosphate, or a mixture thereof. Incertain embodiments, the glidant is colloidal silicon dioxide. Incertain embodiments, the glidant is present in an amount of about 0.1 wt% to about 5 wt % of the placebo layer. In certain embodiments, theglidant is present in an amount of about 0.1 wt %, about 0.2 wt %, about0.3 wt %, about 0.4 wt %, about 0.5 wt %, about 0.6 wt %, about 0.7 wt%, about 0.8 wt %, about 0.9 wt %, about 1 wt %, about 2 wt %, about 3wt %, about 4 wt %, about 5 wt %, or any intermediate valued therein, ofthe active layer.

6.2.3. Push Layer: In certain embodiments, the push layer is locatedadjacent to the active layer. In certain embodiments, the pushlayer/push layer blend includes a swellable hydrophilic polymer, abinder, an osmogen, a lubricant, and a color pigment. In certainembodiments, the push layer/push layer blend further includes a glidantand/or a stabilizer. In certain embodiments, the push layer does notinclude any drug. In certain embodiments, the swellable hydrophilicpolymer is a high molecular weight polyethylene oxide polymer (e.g.,high molecular weight POLYOX®). In certain embodiments, the push layerblend includes granules containing one or more of high molecular weightPOLYOX®, binder, osmogen, stabilizer, and color pigment. In certainembodiments, the glidant and lubricant are present as extragranularexcipients in the push layer blend. In certain embodiments, the osmogenprovides a concentration gradient for osmotic flow of liquid into thecomposition. The rate at which the high molecular weight water-solublepolymer in the push layer absorbs water depends on the osmotic pressuregenerated by the osmogen in the push layer and the permeability of themembrane coating. As the water-soluble polymer in the push layer absorbswater, it expands in volume, which pushes the drug solution orsuspension in the pull layer out of the tablet through a deliveryport/orifice. The compositions release drug at a rate that isindependent of pH and the hydrodynamics of the dissolution medium.

In certain embodiments, the presence of osmotic agents, e.g., POLYOX®and ionic osmogens, e.g., sodium chloride, in the push layer of tabletcore, is critical to produce uniform swelling of the tablet core. Incertain embodiments, the osmotic agents in the push layer comprise highmolecular weight POLYOX® and milled sodium chloride.

In certain embodiments, the high molecular weight POLYOX® in the pushlayer has an average molecular weight of ≥1M, e.g., about 1M (POLYOX®WSR N 12K), about 2M (POLYOX® WSR N 60K), about 4M (POLYOX® WSR 301),about 5M (POLYOX® coagulant), about 7M (POLYOX® WSR 303), or anyintermediate values thereof. In certain embodiments, swelling of POLYOX®coagulant (5M) can be enhanced by mixing with a portion of POLYOX® WSR303 (7M). In certain embodiments, swelling of POLYOX® coagulant can bereduced by mixing with a portion of POLYOX®WSR 301 (4M). In certainembodiments, the high molecular weight POLYOX® is present in an amountof about 50 wt % to about 80 wt % of the push layer. In certainembodiments, the high molecular weight POLYOX® is present in an amountof about 50 wt %, about 55 wt %, about 60 wt %, about 65 wt %, about 70wt %, about 75 wt %, about 80 wt %, or any intermediate values therein,of the push layer.

In certain embodiments, the amount and grade of the high molecularweight POLYOX® in the push layer affects the drug release profile fromthe dosage form, i.e., an increase in the molecular weight or amount ofthe high molecular weight POLYOX® in the push layer will increase thevolume of the push layer and the force exerted on the pull layer forfast and complete drug recovery. In certain embodiments, the grade ofthe high molecular weight POLYOX® in the push layer is selected toprovide rapid expansion and complete drug recovery in about 22 hoursfrom the time of administration of the dosage form. In certainembodiments, the grade of the high molecular weight POLYOX® in the pushlayer is selected to provide rapid expansion without tearing of thesemipermeable membrane.

In certain embodiments, the push layer comprises binders includingpovidone, hypromellose, starch, acacia, gellan gum, low viscosityhydroxypropyl cellulose, methylcellulose, sodium methylcellulose,polyvinyl alcohol, polyvinyl acetates (e.g., KOLLICOAT® SR),polyethylene oxide (e.g., POLYOX®), polyethylene glycol, alginates,pegylated polyvinyl alcohol, or any combination thereof. In certainembodiments, the binder is povidone.

In certain embodiments, the binders are present in an amount of about0.5 wt % to about 20 wt % of the push layer. In certain embodiments, thebinders are present in an amount of about 0.5 wt %, about 0.6 wt %,about 0.7 wt %, about 0.8 wt %, about 0.9 wt %, about 1 wt %, about 2 wt%, about 3 wt %, about 4 wt %, about 5 wt %, about 6 wt %, about 7 wt %,about 8 wt %, about 9 wt %, about 10 wt %, or any intermediates valuestherein, of the push layer.

In certain embodiments, the push layer includes at least one stabilizerto prevent degradation of POLYOX®. In certain embodiments, thestabilizer comprises antioxidants including ascorbic acid and its salts,tocopherols, sulfite salts such as sodium metabisulfite or sodiumsulfite, sodium sulfide, butylated hydroxyanisole (BHA), butylatedhydroxytoluene (BHT), ascorbyl palmitate, propyl gallate, or anycombination thereof. In certain embodiments, the antioxidant is BHT. Incertain embodiments, the stabilizer is present in an amount of about0.01 wt % to about 0.5 wt % of the push layer. In certain embodiments,the stabilizer is present in an amount of about 0.01 wt %, about 0.02 wt%, about 0.03 wt %, about 0.04 wt %, about 0.05 wt %, about 0.06 wt %,about 0.07 wt %, about 0.08 wt %, about 0.09 wt %, about 0.1 wt %, about0.2 wt %, about 0.3 wt %, about 0.4 wt %, about 0.5 wt %, or anyintermediate values therein, of the push layer.

In certain embodiments, the push layer comprises lubricants includingmagnesium stearate, glyceryl monostearates, palmitic acid, talc,carnauba wax, calcium stearate sodium, sodium or magnesium laurylsulfate, calcium soaps, zinc stearate, polyethylene oxide, polyethyleneglycols, polyoxyethylene monostearates, calcium silicate, silicondioxide, hydrogenated vegetable oils and fats, stearic acid, or anycombination thereof. In certain embodiments, the lubricant is stearicacid.

In certain embodiments, the lubricant is present in an amount of about0.1 wt % to about 2 wt % of the push layer. In certain embodiments, thelubricant is present in an amount of about 0.1 wt %, about 0.2 wt %,about 0.3 wt %, about 0.4 wt %, about 0.5 wt %, about 0.6 wt %, about0.7 wt %, about 0.8 wt %, about 0.9 wt %, about 1.0 wt %, about 1.1 wt%, about 1.2 wt %, about 1.3 wt %, about 1.4 wt %, about 1.5 wt %, about1.6 wt %, about 1.7 wt %, about 1.8 wt %, about 1.9 wt %, about 2.0 wt%, or any intermediate values therein, of the push layer.

In certain embodiments, the push layer comprises at least one glidantincluding talc, colloidal silicon dioxide, magnesium trisilicate,powdered cellulose, starch, and tribasic calcium phosphate. In certainembodiments, the glidant is colloidal silicon dioxide. In certainembodiments, the glidant is present in an amount of about 0.1 wt % toabout 5 wt % of the push layer. In certain embodiments, the glidant ispresent in an amount of about 0.1 wt %, about 0.2 wt %, about 0.3 wt %,about 0.4 wt %, about 0.5 wt %, about 0.6 wt %, about 0.7 wt %, about0.8 wt %, about 0.9 wt %, about 1 wt %, about 2 wt %, about 3 wt %,about 4 wt %, about 5 wt %, or any intermediate valued therein, of thepush layer.

In certain embodiments, the push layer comprises at least one osmogen.In certain embodiments, the osmogen comprises ionic compounds ofinorganic salts that provide a concentration differential for osmoticflow of liquid into the composition. The rate at which the highmolecular weight water-soluble polymer in the push layer absorbs waterdepends on the osmotic pressure generated by the push layer and thepermeability of the semipermeable membrane coating. As the water-solublepolymer in the push layer absorbs water, it expands in volume, whichpushes the drug solution or suspension present in the active layer outof the tablet core through a delivery port/orifice in the membrane. Incertain embodiments, the osmogen is an ionic compound comprising sodiumchloride, potassium chloride, potassium sulfate, lithium sulfate, sodiumsulfate, a lactose and sucrose combination, a lactose and dextrosecombination, sucrose, dextrose, mannitol, dibasic sodium phosphate, andcombinations thereof. In certain embodiments, the osmogen is sodiumchloride. In certain embodiments, the osmogen is present in an amount ofabout 5 wt % to about 30 wt % of the push layer. In certain embodiments,the osmogen is present in an amount of about 5 wt %, about 6 wt %, about7 wt %, about 8 wt %, about 9 wt %, about 10 wt %, about 15 wt %, about20 wt %, about 25 wt %, about 30 wt %, or any intermediate valuestherein, of the push layer.

In certain embodiments, the push layer includes at least one colorpigment for identifying the push layer in the multilayered tablet core.In certain embodiments, the push layer and the placebo layer include thesame color pigment. In certain embodiments, the placebo layer containsless amount of color pigment than the push layer. In certainembodiments, the push layer is darker in color than the placebo layer,which helps in identifying the placebo layer side while drilling adelivery orifice in the membrane that is in fluid communication with theplacebo layer. In certain embodiments, the push layer comprises at leastone pigment including iron oxide or lake- based colors. In certainembodiments, the pigment is a lake-based color. In certain embodiments,the pigment is an iron oxide pigment, e.g., oxide pigment red or oxidepigment black. In certain embodiments, the pigment is present in anamount of about 0.5 wt % to about 2 wt % of the push layer.

6.2.4. Semipermeable Membrane: In certain embodiments, the trilayertablet core is coated with a semipermeable membrane. In certainembodiments, the semipermeable membrane is a polymeric film coatingcontaining at least one orifice in fluid communication with placebolayer.

In certain embodiments, the perforation of a semipermeable membrane isachieved through manual or laser drilling. In certain embodiments, theorifice size is less than about 1000 μm. In certain embodiments, theorifice size is about 950 μm, about 900 μm, about 850 μm, about 800 μm,about 750 μm, about 700 μm, about 650 μm, about 600 μm, about 550 μm,about 500 μm, about 450 μm, about 400 μm, about 350 μm, about 300 μm,about 250 μm, or about 200 μm. In certain embodiments, it is importantthat the semipermeable membrane is adequately perforated with an orificewithout compromising the integrity of the tablet core.

In certain embodiments, the coating composition and/or coating weightgain of the semipermeable membrane determines the lag time provided bythe composition. In certain embodiments, the coating weight gain of thesemipermeable membrane ranges from about 1 wt % to about 50 wt %, about5 wt % to about 45 wt %, about 5 wt % to about 40 wt %, about 5 wt % toabout 35 wt %, about 5 wt % to about 30 wt %, from about 5 wt % to about25 wt %, from about 5 wt % to about 20 wt %, from about 5 wt % to about15 wt %, from about 5 wt % to about 10 wt %, or any intermediate rangestherein, of the tablet core weight.

In certain embodiments, the semipermeable membrane coat over themultilayered tablet core is substantially impermeable to drugs andexcipients present in the programmable osmotic-controlled oralcomposition. In certain embodiments, the semipermeable membrane is inertand maintains its integrity to provide constant osmotic pressure duringdrug delivery. In certain embodiments, the semipermeable membranecomprises one or more pH-independent water-insoluble polymers that arepermeable to water and substantially impermeable to solutes, e.g., drugsand excipients. Polymers suitable for inclusion in the semipermeablemembrane comprise cellulose esters, e.g., cellulose acetate, celluloseacetate butyrate, and cellulose triacetate. In certain embodiments, thesemipermeable membrane comprises cellulose acetate. In certainembodiments, the permeability of the semipermeable membrane can beenhanced by increasing the acetyl content in cellulose acetate. Incertain embodiments, the semipermeable membrane comprises celluloseacetate with at least about 35% acetyl content. In certain embodiments,the semipermeable membrane comprises cellulose acetate with about 39.8%acetyl content. In certain embodiments, permeability of thesemipermeable membrane is enhanced by addition of water-soluble poreformers to the membrane composition. In certain embodiments, thewater-soluble pore formers comprise polyethylene glycol (PEG 400, PEG1000, PEG 1450, PEG 3350), hydroxypropyl cellulose, polyvinyl pyrolidone(PVP), KOLLIDON® 30, KOLLICOAT® IR, mannitol, and methyl cellulose(METHOCEL™ E3, METHOCEL™ E5, METHOCEL™ E6), poloxamers, e.g., poloxamer188, triethyl citrate, triacetin, hydroxypropyl methylcellulose,glycerol, and combination thereof. In certain embodiments, thesemipermeable membrane comprises cellulose acetate and a pore-formingcopolymer such as polypropylene glycol and/or poloxamers, e.g.,poloxamer 188. In certain embodiments, the ratio of cellulose acetate topolyethylene glycol is between about 80:20 and about 99.5:0.5. Incertain embodiments, the ratio of cellulose acetate to poloxamer isbetween about 80:20 and about 99.5:0.5. In certain embodiments, ratio ofcellulose acetate and pore former affects variability in lag time. Incertain embodiments, variability in lag time decreases with increasingthe amount of pore former in the membrane. In certain embodiments, lagtime decreases with increasing the amount of pore former in themembrane. In certain embodiments, the ratio of cellulose acetate andpore former is optimized to obtain a desired lag time with minimalvariability. In certain embodiments, the ratio of cellulose acetate andpore former is about 80:20, about 85:15, about 90:10, about 95:5, about96:4, about 97:3, about 98:2, about 99:1, about 99.5:0.5, or anyintermediate values therein.

In certain embodiments, the semipermeable membranes include one or moreplasticizers. Plasticizers play a significant role in adjustingflexibility and permeability of the semipermeable membrane. Plasticizerschange the viscoelastic behavior and permeability of the polymer presentin the semipermeable membrane. Plasticizers used in the semipermeablemembranes comprise polyethylene glycols, triethyl citrate, triacetin,diethyl tartrate, and combinations thereof. In certain embodiments, thepore former comprises polyethylene glycol (PEG 400, PEG 1000, PEG 1450,PEG 3350), hydroxypropyl cellulose, polyvinyl pyrolidone (PVP),KOLLIDON® 30, KOLLICOAT® IR, mannitol, and methyl cellulose (METHOCEL™E3, METHOCEL™ E5, METHOCEL™ E6).

In certain embodiments, solvents for coating comprise water, acetone,and/or any mixtures thereof. In certain embodiments, the programmableosmotic-controlled oral compositions of the disclosure include anaesthetic coat over the semipermeable membrane. In certain embodiments,the aesthetic coat comprises colors, flavors, and sweeteners. In certainembodiments, the aesthetic coat is the outermost coat comprising OPADRY®II for pigmentation or OPADRY® clear for final glossiness. In certainembodiments, the aesthetic coat further comprises wax to improve flowfor packaging.

6.2.5. Active Pharmaceutical Agents: In certain embodiments, theprogrammable osmotic-controlled oral compositions of the disclosure aresuitable for drugs/active pharmaceutical agents comprising any level ofaqueous solubilities.

In certain embodiments, drugs suitable for the programmableosmotic-controlled composition of the disclosure include CNS-actingdrugs, cardiovascular-acting drugs, anti-infectives, analgesics,anesthetics, antiarthritics, antiasthmatics, anticonvulsants,antidepressants, antidiabetics, antidiarrheals, antihistamines,anti-inflammatories, antimigraines, antineoplastics, antiparkinsondrugs, antipruritics, antipsychotics, antipyretics, antispasmodics,anticholinergics, sympathomimetics, calcium channel blockers, betablockers, antiarrhythmics, antihypertensives, ACE inhibitors, diuretics,vasodilators, decongestants, hormones, hypnotics, immunosuppresives,parasympathomimetics, prostaglandins, proteins, peptides, sedatives andtranquilizers.

In certain embodiments, drugs suitable for delayed release includeamphetamines, methylphenidate, diltiazem, carbamazepine, metoprolol,oxprenolol, nifedipine, albuterol, phenylpropanolamine, pseudoephedrine,chlorpheniramine maleate, prazosin, doxazosin, verapamil, oxybutyninchloride, isradipine, hydromorphone, paliperidone, modafinil,armodafinil, liothyronine, oseltamivir (Tamiflu), rifamycin, andglipzide.

In certain embodiments, compositions of the disclosure provide chronodrug release and are designed to treat, e.g., diseases in whichbiological rhythm(s) play a vital role in the pathophysiology of suchdiseases to avoid degradation of bioactive agents. In certainembodiments, the compositions of the disclosure are used to treatconditions that require chrono drug release, e.g., attention disorders,asthma, arthritis, congestive heart failure, myocardial infarction,stroke, cancer, peptic ulcer, epilepsy, migraine, pain, etc., whereinthe risk and symptoms of the disease vary predictably over time.

In certain embodiments, chrono release compositions of the disclosureinclude antibiotics such as gentamycin, tobramycin, and amikacin;antihypertensives such as nifedipine, oral nitrates, propranolol, andatenolol; antiepileptic drugs such as valproic acid; anti-inflammatorydrugs such as indomethacin and ketoprofen; anti-asthmatic drugs such astheophylline and beta sympathomimetics; anti-ulcer drugs such asranitidine, cimetidine, and famotidine; anticancer drugs; NSAIDs fortreating arthritis; antihyperlipidemic drugs, such as statins; opioidanalgesics such as tramadol; antimigraine drugs such as sumatriptan;immunosuppressants such as cyclosporine; local anesthetics such aslidocaine, ropivacaine, mepivacaine, and betoxycaine; and generalanesthetics such as barbiturates.

In certain embodiments, immediate release sedatives suitable for theprogrammable osmotic-controlled compositions of the disclosure includeclonidine, diphenhydramine, guanfacine, and/or melatonin.

6.3. Embodiments of the Dosage Form: In certain embodiments, additionalprogrammable osmotic-controlled compositions containing additional pulllayers, IR coatings, etc. are contemplated. A nonlimiting set ofexemplary osmotic-controlled compositions follows.

In certain embodiments, the programmable osmotic-controlled compositionof the disclosure comprises a combination composition providing animmediate release of a sedative and a delayed extended release of astimulant. In certain embodiments, the programmable osmotic-controlledcomposition of the disclosure comprises a multilayer tablet core coatedwith a semipermeable membrane containing an orifice, and a coating of asedative for immediate release, over the semipermeable membrane. Incertain embodiments, the tablet core comprises multiple layers in thefollowing order: a placebo layer in fluid communication with orifice inthe semipermeable membrane, a delayed extended release layer containinga stimulant, and a push layer, wherein the push layer is away (e.g.,furthest away) from the orifice in the semipermeable membrane.

In certain embodiments, the programmable osmotic-controlled compositionof the disclosure is a combination composition providing an extendedrelease of a sedative and a delayed extended release of a stimulant. Incertain embodiments, the programmable osmotic-controlled composition ofthe disclosure comprises an IR coat containing a sedative, a seal coatbelow the IR sedative coat, an ER coat containing a sedative and belowthe seal coat, a cellulose acetate coat containing an orifice below theER sedative coat, a “placebo” layer in fluid communication with theorifice, a delayed extended release layer containing a stimulant andplaced below the placebo layer, and a push layer placed below thedelayed extended release layer and facing away from the orifice.

In certain embodiments, the programmable osmotic-controlled compositionof the disclosure comprises a combination composition providingimmediate release of a sedative and a chrono release of a stimulant. Incertain embodiments, the composition comprises a multilayer tablet corecoated with a semipermeable membrane containing an orifice, and acoating of a drug for immediate release over the semipermeable membrane.

In certain embodiments, the multilayered tablet core comprises a pushlayer, and a pull layer comprising a placebo layer and an active layercontaining a stimulant, wherein the active layer comprises an immediaterelease layer and an extended release layer for providing chrono releaseof the stimulant. In certain embodiments, the tablet core comprisesmultiple layers in the following order: a placebo layer in fluidcommunication with the orifice in the semipermeable membrane, a delayedimmediate release layer containing a stimulant, a delayed extendedrelease layer containing a stimulant, and a push layer, wherein the pushlayer is furthest away from the orifice in the semipermeable membrane.In certain embodiments, the delayed immediate release layer and thedelayed extended release layer contain the same stimulant.

In certain embodiments, the programmable osmotic-controlled compositionof the disclosure comprises a combination composition providing animmediate release of a sedative and a delayed chrono release of astimulant, wherein the immediate release sedative is present as animmediate release layer in the tablet core. In certain embodiments, thetablet core comprises multiple layers in the following order: animmediate release layer containing a sedative and in fluid communicationwith the orifice in the semipermeable membrane, a placebo layer, adelayed immediate release layer, containing a stimulant, a delayedextended release layer containing a stimulant, and a push layer facingaway from the orifice. In certain embodiments, the delayed immediaterelease layer and the delayed extended release layer contain the samestimulant.

In certain embodiments, the programmable osmotic-controlled compositionof the disclosure provides pulsatile release of a drug. In certainembodiments, the composition comprises a multilayer tablet core coatedwith an IR coat comprising a drug, and a coating of a semipermeablemembrane containing an orifice below the IR coat. In certainembodiments, the tablet core comprises multiple layers in the followingorder: a placebo layer in fluid communication with the orifice in thesemipermeable membrane, a delayed immediate release layer comprising thedrug, and a push layer, to provide pulsatile release of a drug in twopulses. In certain embodiments, the tablet core comprises a firstplacebo layer in fluid communication with the orifice in thesemipermeable membrane, a first delayed immediate release layercomprising a stimulant, a second placebo layer, a second delayedimmediate release layer, and a push layer, to provide a pulsatilerelease of a drug in three pulses.

In certain embodiments, the programmable osmotic-controlled compositionof the disclosure comprises a combination composition providing animmediate release of a sedative and a delayed increasing (gradient)release of a stimulant. In certain embodiments, the compositioncomprises a multilayer tablet core coated with a semipermeable membranecontaining an orifice. In certain embodiments, the tablet core comprisesmultiple layers in the following order: a placebo layer in fluidcommunication with the orifice in the semipermeable membrane, at leasttwo delayed release layers comprising a stimulant for delayed release,and a push layer, wherein the at least two delayed release layersreleases the stimulant over a period of at least two successiveintervals, wherein more stimulant is released in the second intervalcompared to the first interval.

In certain embodiments, the viscosity of the placebo layer, the activelayer, and the push layer, and the drug to polymer ratio in the activelayer determine the release rate of the drug as an immediate releaseportion or an extended release portion. In certain embodiments, animmediate release layer will comprise a higher drug to polymer ratiocompared to an extended release layer containing the same drug and thepolymer.

In certain embodiments, the dosage form of the disclosure comprises animmediate release coat and an extended release coat of the sedative, andthe two coats are separated by a seal coat.

In certain embodiments, the seal coat comprises hydroxypropyl methylcellulose (HPMC), hydroxypropyl cellulose, hydroxyethyl cellulose, orpovidone. In certain embodiments, the seal coat is present in an amountof between about 1 wt % to about 20 wt %, about 5 wt % to about 20 wt %,or about 5 wt % to about 15 wt % of the tablet core weight without sealcoat.

In certain embodiments, the exemplary clinical situation describedherein involves treatment of ADHD/ADD with an immediate release sedativeand delayed release stimulant therapy. Accordingly, the presentdisclosure also pertains to making oral methylphenidate delayed releasedosage forms that provide an immediate release of a sedative and delayedrelease of methylphenidate over an extended time period.

6.4. Features of the Dosage Form

The present disclosure provides programmable osmotic-controlled oralcompositions that provide delayed controlled release of a drug, and canbe programmed to release drug at a desired time and for a desiredduration, e.g., at a rhythm that matches the requirements for treatmentin a sleep/wake cycle, or at a rhythm that matches the human circadianrhythm of a condition's symptom and/or of the individual being treatedin the application of the therapy, with complete drug recovery. Theosmotic-controlled oral compositions of the disclosure can be programmedto control lag time during the delay period and release drug at adesired rate after the delay period. In certain embodiments, theosmotic-controlled oral compositions are programmed to provide a preciselag time of at least about 4, 5, 6, 7, 8, 9, 10, 11, 12 hours, orintermediate time periods within the range. In certain embodiments, theprogrammable osmotic-controlled oral compositions of the disclosureprovide delayed extended release, delayed chrono release, delayedpulsatile release, and pulsatile release of drugs with various doses andsolubilities, and can be programmed to release drug at a rate thatmatches the human circadian rhythm of a condition's symptom and/or ofthe individual being treated in the application of the therapy. Theprogrammable osmotic-controlled oral compositions of the disclosureprovide pH-independent drug release at an osmotically determined ratefor an extended time period, even as the dosage form transits the GItract and encounters variable hydrodynamic environments of the GI tract,as well as microenvironments with significantly different pH values. Incertain embodiments, the programmable osmotic- controlled oralcompositions of the disclosure provide delayed controlled release of adrug, with minimum variability in lag time in response to varying pH andhydrodynamic conditions of a dissolution medium or the human GI tract.

In certain embodiments, the programmable osmotic-controlled oralcompositions of the disclosure provide an immediate release of asedative and delayed extended release of methylphenidate hydrochloride.In certain embodiments, the timing of administration of the composition(e.g., in the evening) is titrated to optimize the tolerability andefficacy of the dose, as seen during, e.g., the next morning andthroughout the day. In certain embodiments, the osmotic-controlled oralcompositions of the active agent (e.g., methylphenidate) are programmedto provide drug release as follows: a lag time of at least about, e.g.,6-8 hours, a controlled release comprising about 20% of drug release inabout 1-4 hours after the lag time, and an extended release of the drugwith about 100% drug recovery in about 10-15 hours after the lag time(or about 22 hours from the time of administration of the composition).In certain embodiments, the disclosure provides programmableosmotic-controlled oral compositions of, e.g., methylphenidate that canbe programmed to limit the amount of methylphenidate in plasma to lessthan about 10% of the maximum concentration (Cmax) during the lag timeto avoid side effects, e.g., insomnia; in addition, the programmableosmotic-controlled oral compositions limit the amount of methylphenidatein plasma to less than about 10% of the Cmax beginning about 22 hoursafter the time of administration, to avoid side effects, e.g., insomnia.

The programmable osmotic-controlled oral compositions of the disclosurecan comprise a multilayer tablet core comprising a drug, wherein thecore is coated with a semipermeable membrane comprising an orifice and,optionally, an immediate release drug layer coating/immediate releasedrug layer, comprising a drug for immediate release, over thesemipermeable membrane. In certain embodiments, the immediate releasedrug layer coating includes therapeutically effective doses of two ormore pharmaceutically active ingredients or pharmaceutically effectivesalts thereof. In certain embodiments, the multilayered tablet corecomprises a push layer and a pull layer. In certain embodiments, thepull layer comprises a placebo layer and an active layer. In certainembodiments, the active layer comprises a drug for delayed extendedrelease. In certain embodiments, the drug in the immediate release druglayer coating and the drug in the active layer are different. In certainembodiments, the delayed extended release is a delayed chrono releasecomprising a delayed immediate release and a delayed extended release.In certain embodiments, the placebo layer is in fluid communication withthe orifice.

In certain embodiments, the disclosure provides programmable osmotic-controlled oral compositions providing pulsatile release of a drug. Incertain embodiments, the programmable osmotic-controlled oralcompositions of the disclosure comprise a multilayered tablet corecomprising layers in the following order: a placebo layer in fluidcommunication with the orifice in the semipermeable membrane, an activelayer, a (second) placebo layer, an (second) active layer, and a pushlayer, wherein the push layer is away (e.g., furthest away) from theorifice in the semipermeable membrane. In certain embodiments, thepulsatile release comprises pulses of drug release separated by awell-defined lag time(s). In certain embodiments, the pulsatile releaseis a delayed pulsatile release.

In certain embodiments, the programmable osmotic-controlled oralcompositions of the disclosure are programmed to obtain a desired lagtime by adjusting the composition of the placebo layer and/or the pushlayer, e.g., the amount and/or molecular weight/grade of thepolyethylene oxide polymer (e.g., POLYOX®) in the placebo layer and/orthe push layer, the coating composition of the semipermeable membrane,and/or the coating level of the semipermeable membrane.

In certain embodiments, the amount and/or molecular weight of thePOLYOX® in the placebo layer can affect lag time. In certainembodiments, the placebo layer provides a desired lag time by delayingthe release of the active pharmaceutical ingredient/drug in theenvironment of use. In certain embodiments, the lag time depends uponthe amount/volume of the placebo layer that must be displaced by theexpanding push layer. In certain embodiments, the lag time depends uponthe molecular weight/grade of the POLYOX® (e.g., POLYOX® grade) presentin the placebo layer. In certain embodiments, the lag time increaseswith increasing the molecular weight/grade of the POLYOX® present in theplacebo layer. In certain embodiments, the volume of the placebo layerdepends upon the amount of POLYOX® present in the placebo layer. Incertain embodiments, the lag time increases as the amount of POLYOX® inthe placebo layer increases. FIG. 23 demonstrates that compositions withplacebo layers containing POLYOX®, with an average molecular weight ofat least about 300K, provide a lag time of at least about 6 hours. FIG.14 compares lag times of compositions of the disclosure containingPOLYOX® 1105 (MW of 900K) and POLYOX® 205 (MW of 600K) in the placebolayer. The Figure demonstrates that compositions containing POLYOX® 1105in the placebo layer exhibit a longer lag time compared to compositionscontaining POLYOX® 205. In certain embodiments, compositions containingPOLYOX® 1105 in the placebo layer do not exhibit a change in lag timewith increasing the amount of POLYOX® in the placebo layer. FIG. 7 showsthat the programmable osmotic-controlled oral compositions of thedisclosure, containing POLYOX® 1105 in the placebo layer, and having adrug to polymer weight ratio of about 28:72, do not show any change inlag time with change in the amount of the POLYOX® in the placebo layer.FIG. 8 shows that the programmable osmotic-controlled compositions ofthe disclosure do not show any change in lag time with POLYOX® 1105 orPOLYOX® 205.

In certain embodiments, the amount and/or molecular weight of thePOLYOX®in the push layer can affect lag time. FIG. 15 shows a decreasein lag time with an increase in amount of POLYOX® in push layer. Incertain embodiments, the variation in lag time with the volume/amount ofpush layer is minimized when the drug layer comprises a drug to polymerweight ratio of about 40:60 and/or the placebo layer comprises POLYOX®having a molecular weight of at least about 600K, e.g., POLYOX® 205 orPOLYOX® 1105. FIG. 17 shows that programmable osmotic-controlled oralcompositions of the disclosure containing POLYOX® 1105 in the placebolayer, and having a drug to polymer weight ratio of about 40:60, do notshow any change in lag time, with a change in the volume/amount of thepush layer. In certain embodiments, the amount/volume of the push layercan be changed by changing the amount of sodium chloride and/or thePOLYOX® in the push layer.

In certain embodiments, the amount of osmogen, e.g., sodium chloride, inthe active layer can affect lag time. FIG. 14 demonstrates thatprogrammable osmotic-controlled oral compositions of the disclosurecontaining POLYOX® 205 in the placebo layer show a decrease in lag timewith an increase in the amount of sodium chloride in the active layer.In certain embodiments, the presence of sodium chloride in the activelayer increases the rate of hydration of POLYOX® in the active layer andimproves drug recovery without changing the lag time. FIG. 10demonstrates that programmable osmotic-controlled oral compositions ofthe disclosure containing POLYOX® 1105 in the placebo layer show nochange in lag time with the presence of sodium chloride in the activelayer. FIG. 10 demonstrates that the presence of sodium chloride in theactive layer improves drug recovery without affecting lag time.

In certain embodiments, the presence of sodium chloride in the pushlayer affects lag time, release rate, and/or drug recovery of thecomposition. In certain embodiments, the presence of sodium chloride inthe push layer increases hydration and gelling of POLYOX® present in thepush layer, which increases the release rate and drug recovery from thecomposition. FIG. 11 shows the effect of the presence of sodium chloridein the push layer on drug recovery and lag time. FIG. 11 demonstratesthat programmable osmotic-controlled oral compositions of the disclosurecontaining POLYOX® 205 in the placebo layer and having a drug to polymerratio of about 30:70, show a decrease in lag time with the addition ofsodium chloride into the push layer.

FIG. 11 further demonstrates that a lag time of at least about 6 hoursis obtained with the presence of about 10% to about 18% of sodiumchloride in the push layer; and the lag time remains unchangedthereafter with any further increase in sodium chloride amount in thepush layer.

In certain embodiments, the drug to polymer weight ratio in the activelayer affects lag time and drug recovery at 24 hours. In certainembodiments, an increase in drug to polymer weight ratio in the activelayer decreases lag time while providing higher drug recovery comparedto corresponding compositions with lower drug to polymer weight ratio inthe active layer. In certain embodiments, a drug to polymer weight ratioof about 28:72 improves drug recovery at 24 hours, without affecting thelag time, when compared with compositions having a drug to polymerweight ratio of about 20:80. In certain embodiments, the presence ofsodium chloride in the active layer improves drug recovery at 24 hourswithout affecting lag time. In certain embodiments, an active layercontaining a drug to polymer weight ratio of 40:60 requires sodiumchloride in an amount of at least about 3 wt % of the active layer toprovide a lag time of at least 6 hours.

In certain embodiments, the placebo layer is substantially free ofosmogen and disintegrant/wicking agent. It was surprisingly observedthat the programmable osmotic-controlled oral compositions of thedisclosure provide a lag time of at least 6 hours in the absence of anosmogen/water entraining agent and/or in the absence of adisintegrant/wicking agent in the placebo layer. FIG. 25 comparesdissolution rate of Tablet 52 and Tablet 53. The Figure demonstratesthat addition of superdisintegrant and sodium chloride in placebo layerreduces the drug recovery without affecting lag time.

In certain embodiments, the lag time and drug recovery depend upon themembrane composition and coating weight gain/coating level of themembrane. In certain embodiments, the membrane is a semipermeablemembrane comprising at least one water-insoluble polymer and a poreformer. In certain embodiments, the membrane comprises cellulose acetate(CA) and polyethylene glycol (PEG) with a CA to PEG ratio of betweenabout 80:20 and about 99.5:0.5. In certain embodiments, the membranecomprises OPADRY® CA with CA to PEG ratio of about 95:5 or about 98:2.In certain embodiments, increasing the amount of cellulose acetate inthe membrane reduces drug recovery and increases lag time. FIG. 12compares drug recovery and lag time between compositions of thedisclosure comprising OPADRY® CA (CA:PEG ratio of 95:5) and OPADRY® CA(98:2). FIG. 12 demonstrates that compositions containing OPADRY® CA(95:5) provide better drug recovery compared to compositions containingOPADRY® CA (98:2). In certain embodiments, the lag time increases withincreasing the coating weight gain/coating level of the semipermeablemembrane. In certain embodiments, drug recovery is reduced, and lag timeis increased with increasing coating weight gain of the semipermeablemembrane. FIG. 18 demonstrates that lag time increases and drug recoverydecreases with an increase in the coating weight gain from about 12.5%to about 15%.

In certain embodiments, the compositions of the disclosure do notexhibit any change in lag time with changing hydrodynamics and viscosityof the dissolution medium. FIG. 21 compares in vitro release profiles ofcompositions as determined in

USP Apparatus II with a paddle speed of 50 rpm in 0.01 N HCl at 37° C.,and in USP Apparatus III with agitation at 25 dpm in 0.01 N HCl at 37°C., conditions simulating hydrodynamics of the GI tract. FIG. 21demonstrates that there is no substantial change in lag time withhydrodynamics of the dissolution medium simulating GI conditions. FIG.20 compares dissolution rates of compositions in dissolution mediumswith different viscosities. FIG. 20 demonstrates that there is no changein lag time with changing viscosity of the dissolution medium simulatingGI medium.

In certain embodiments, the POLYOX® grade in the push layer affects drugrecovery and release profile of the composition. FIG. 24 compares therelease rate and drug recovery of compositions containing POLYOX® WSR303 (7M), POLYOX® WSR 301 (3M), and POLYOX® WSR Coagulant (5M) in thepush layer. FIG. 24 demonstrates that compositions containing POLYOX®303 in the push layer provide faster release profiles and lower drugrecovery, compared to compositions containing POLYOX® WSR 301 or POLYOX®WSR Coagulant in the push layer. This can be due to reduced standarddeviation in POLYOX® WSR 301 or POLYOX® WSR Coagulant compared toPOLYOX® 303.

In certain embodiments, the compositions of the disclosure release nomore than about 10% of the active pharmaceutical ingredient followed byextended release for about 10-16 hours, when the composition is placedin a dissolution medium comprising about 900 ml of aqueous solution ofabout 0.01N HCl, pH about 2.0, for up to 24 hours, as measured in USPApparatus II, at 37° C. and agitation at 50 rpm. In certain embodiments,the compositions of the disclosure release no more than about 9%, nomore than about 8%, no more than about 7%, no more than about 6%, nomore than about 5%, no more than about 4%, no more than about 3%, nomore than about 2%, and no more than about 1% of the activepharmaceutical ingredient followed by extended release for about 10-16hours, when the composition is placed in a dissolution medium comprisingabout 900 ml of aqueous solution of about 0.01N HCl, pH about 2.0, forup to 24 hours, as measured in USP Apparatus II, at 37° C. and agitationat 50 rpm.

6.5. Methods of Treating

In certain embodiments, the programmable osmotic-controlled compositionsof the disclosure delay the release of a drug and/or release drug at arhythm that matches the human circadian rhythm of a condition's symptomsand/or of the individual being treated in the application of the therapyto optimize therapeutic outcome and minimize side effects. In certainembodiments, the programmable osmotic-controlled compositions of thedisclosure can be used for treating conditions that require release ofdrug following circadian rhythm of the conditions, e.g., central nervoussystem (CNS) disorders, asthma, arthritis, congestive heart failure,myocardial infarction, stroke, cancer, peptic ulcer, narcolepsy,epilepsy, migraine, pain, etc., wherein the risks and symptoms of thedisease vary predictably over time. In certain embodiments, thecomposition can be administered at night (e.g., before bedtime, e.g.,about 8.00 pm) and the drug release is delayed for about 4 to about 10hours or longer, followed by an extended release, pulsatile release, ora chrono drug release.

In certain embodiments, the programmable osmotic-controlled compositionsof the disclosure provide delayed release of a stimulant used for thetreatment of ADHD/ADD. Treatment of ADHD/ADD with stimulants helps toimprove symptoms of ADHD, as well as to improve self-esteem, cognition,and social and family interactions of the patient. The most commonlyprescribed medications for ADHD include mixed amphetamines andmethylphenidate. These medications have calming and focusing effects onan individual suffering from ADHD. Mixed amphetamines suitable for usein the programmable osmotic-controlled compositions of the disclosureinclude dextroamphetamine, d,l amphetamines, and pharmaceuticallyacceptable salts thereof, for example a mixture of amphetamineaspartate, amphetamine sulfate, dextroamphetamine sulfate, anddextroamphetamine saccharate.

Methylphenidate is a CNS stimulant approved by the FDA in 1955 forhyperactivity. Methylphenidate can be prescribed in a racemic mixture ofdextro and levo conformations or as a pure dextro isomer. The use ofpharmaceutically acceptable salts of methylphenidate, such asmethylphenidate hydrochloride, is also contemplated in the presentdisclosure.

In certain embodiments, the programmable osmotic-controlled compositionsof methylphenidate comprise a multilayered tablet core coated with asemipermeable membrane containing an orifice. In certain embodiments,the multilayered tablet core comprises a push layer, and a pull layercontaining methylphenidate hydrochloride. In certain embodiments, thepull layer comprises a placebo layer, and an active layer, wherein theactive layer contains methylphenidate hydrochloride. In certainembodiments, the placebo layer provides a lag time for the delay inrelease of methylphenidate hydrochloride. In certain embodiments, theplacebo layer does not include any drug. In certain embodiments, theplacebo layer can include a small amount of a drug for immediaterelease. In certain embodiments, drug for IR in placebo layer is notmethylphenidate or a pharmaceutically acceptable salt thereof. Incertain embodiments, the disclosure provides programmableosmotic-controlled compositions of methylphenidate that are administeredat night, e.g., before bedtime, and deliver a therapeutic amount ofmethylphenidate hydrochloride in a delayed extended release pattern inorder to maintain a constant release of a therapeutic amount ofmethylphenidate hydrochloride throughout the active periods of the day,including upon waking. In certain embodiments, the composition providesa delayed chrono release of methylphenidate hydrochloride.

In certain embodiments, the disclosure provides therapeutic compositionsand methods for treatment of attention deficit disorder (ADD), attentiondeficit hyperactive disorder (ADHD), or other attention disorderconditions responsive to central nervous system (CNS) stimulants. Incertain embodiments, the disclosure provides a method of treatingattention disorders in children, comprising administering to a child inneed thereof a programmable osmotic-controlled composition of thedisclosure providing an immediate release of a sedative, and a delayedrelease of a CNS stimulant, e.g., methylphenidate. The immediate releaseof a therapeutic amount of sedative helps the child sleep during thenight, and a delayed and extended release of a therapeutic amount of aCNS stimulant keeps the child alert throughout the active periods of theday, including when the child is waking up. In certain embodiments, therelease of stimulant is delayed for at least about 6 hours followed byan extended release or a chrono release of the stimulant. In certainembodiments, the delayed release of the stimulant is delayed chronorelease. In certain embodiments, the delayed chrono release is delayedimmediate release and a delayed extended release of the stimulant. Incertain embodiments, the sedative is clonidine, diphenhydramine,guanfacine, or melatonin. In certain embodiments, the CNS stimulant ismethylphenidate hydrochloride. In certain embodiments, the compositionis administered before the child goes to bed. In particular, forpediatric patients with ADHD/ADD, once daily doses of suchosmotic-controlled oral compositions of the disclosure at bedtimeproviding an immediate release of a sedative, e.g., clonidine,guanfacine, diphenhydramine, melatonin, for promoting sedation duringnighttime, followed by delayed extended release or chrono release of aCNS stimulant, e.g., methylphenidate, that starts working in the morningand lasts during the daytime, addresses problems of insomnia duringnight, while keeping the child alert and attentive during the day whenthe child is in school or engaged in activities. In certain embodiments,the release of methylphenidate is delayed for at least about 4 hours, atleast about 5 hours, at least about 6 hours, at least about 7 hours, atleast about 8 hours, at least about 9 hours, at least about 10 hours, atleast about 11 hours, at least about 12 hours, or any intermediateperiods. The composition provides a suitable lag time such that thesedative is effective during the sleep time of the patient, and thestimulant is effective during the day.

In certain embodiments, the disclosure provides programmableosmotic-controlled methylphenidate compositions providing improvedpatient compliance and convenience. The compositions provide clinicalbenefits of delivering methylphenidate hydrochloride in a delayed andextended manner, independent of drug chemical properties, patientphysiological factors, and food. In certain embodiments, the disclosedcompositions provide a timed, prolonged therapeutic effect when takenonce a day. The programmable osmotic-controlled methylphenidatecompositions of the disclosure provide food-independent delayed releasethat can avoid early morning dosing of methylphenidate hydrochloridestimulant to children suffering from ADHD/ADD. The compositions can beadministered, with or without food, at night, before bedtime, e.g.,about 8:00 pm (although other dosing times are contemplated), andprovide delayed controlled release of a stimulant, e.g.,methylphenidate. In certain embodiments, the osmotic-controlledcompositions of methylphenidate avoid insomnia by limiting residualamount of methylphenidate hydrochloride in plasma to less than about 10%of the maximum concentration (Cmax) during the lag time (e.g., the dailylag time).

In certain embodiments, the disclosure provides programmableosmotic-controlled compositions for treating diseases or conditionscomprising attention deficit disorder (ADD), attention deficithyperactive disorder (ADHD), narcolepsy, excessive daytime sleepiness,adrenal insufficiency, major depressive disorder, bipolar disorder,bipolar depression, negative symptoms in schizophrenia, chronic fatigue,or a binge-eating disorder. Typically, stimulant-based medications forADHD/ADD are dosed two hours prior to beginning an early morningroutine, with an onset of treatment effect usually about two hours afteradministration. Such medications require twice-daily administration andcause compliance issues. The compositions of the disclosure avoid theneed of early morning dosing that requires an onset time of about twohours and improve the symptoms of a condition in the early morning andthroughout the day. Early morning symptom control, including getting thechildren ready for school, is a major challenge for parents andcaregivers of children suffering from ADHD/ADD. The programmableosmotic-controlled compositions of the disclosure provide a convenientmethod of administration in that a single dose can be taken (typicallyin the evening prior to going to bed, or at whatever time of the day oneretires for an extended period of sleep) and the release of drug isdelayed for at least about 4 hours, e.g., about 6-12 hours.

The present disclosure provides compositions that can improve thesymptoms of a condition in the early morning and throughout the day,without the need for early morning dosing that requires an onset time ofabout two hours. The present disclosure provides programmableosmotic-controlled oral compositions comprising methylphenidatehydrochloride or mixed amphetamines. Such compositions address thelong-felt need of providing food-independent delayed release that canavoid burdensome early morning dosing of methylphenidate/mixedamphetamine stimulants to children suffering from ADHD/ADD. Thecompositions of the disclosure provide a desired lag time that isindependent of the presence or absence of food, type of food, pH,gastric emptying, and volume of fluid in the GI tract. The compositionscan be administered, with or without food, at night, before bedtime(e.g., at about 8 pm), and provide delayed controlled release of theactive stimulant, e.g., methylphenidate/mixed amphetamines.

In certain embodiments, the methylphenidate/mixed amphetaminecompositions of the disclosure provide an immediate release of asedative, e.g., clonidine, diphenhydramine, guanfacine or melatonin, anda delayed controlled release of a CNS stimulant, e.g., methylphenidateor mixed amphetamine salts. In certain embodiments, the compositions ofthe disclosure do not include any sedative. The compositions can beadministered, with or without food, at night, before bedtime and providea delayed release of the stimulant. In certain embodiments, thecompositions of the disclosure provide minimal variability in lag timein various hydrodynamic conditions and pH (both conditions and regions)of the GI tract. In certain embodiments, the timing of administration istitrated to optimize the tolerability and efficacy the next morning andthroughout the day. In certain embodiments, the compositions of thedisclosure avoid insomnia by limiting the residual amount ofmethylphenidate in plasma to less than about 10% of the maximumconcentration (Cmax) during the determined/planned lag time. In certainembodiments, the compositions of the disclosure limit the residualamount of methylphenidate in plasma to less than about 9%, less thanabout 8%, less than about 7%, less than about 6%, less than about 5%,less than about 4%, less than about 3%, less than about 2%, and lessthan about 1% of the maximum concentration (Cmax).

In certain embodiments, the disclosure provides programmableosmotic-controlled compositions providing delayed pulsatile release of adrug, e.g., osmotic-controlled pulsatile release compositions. Incertain embodiments, the osmotic-controlled pulsatile releasecompositions of the disclosure contain drugs that undergo rapidfirst-pass metabolism and/or require colonic drug delivery. In certainembodiments, the compositions of the disclosure provide plasma peakconcentration at an optimal time, based on circadian rhythm of acondition, and reduce the number of required doses per day by saturatingthe first-pass metabolism.

6.6. Methods of Making

In certain embodiments, the disclosure provides methods for preparingprogrammable osmotic-controlled compositions providing delayed releaseof a drug. In certain embodiments, the delayed release of the drug is ata rhythm that matches the human circadian rhythm of a condition'ssymptoms and/or of the individual being treated in the application ofthe therapy.

Depending on the physiochemical properties, e.g., solubility, stability,particle size, and compaction properties of the drug, theosmotic-controlled compositions of the disclosure are made by wetgranulation, dry granulation, or direct compression.

In certain embodiments, the multilayered programmable osmotic-controlledcompositions of the disclosure are made by wet granulation, wherein thewet granules comprising drug, swellable hydrophilic polymer, and otherexcipients are dried, milled, blended with extragranular excipients, andcompressed into multilayered tablet cores. The resulting tablet coresare coated with a semipermeable membrane coat followed by laser drillingof an orifice in the coating, and, optionally, coating of an immediaterelease drug layer/coat over the semipermeable membrane layer/coat. Incertain embodiments, the semipermeable membrane coat includes awater-soluble pore former. In certain embodiments, the water-solublepore former is a water-soluble plasticizer. In certain embodiments, theimmediate release layer is further coated with an over coat. In certainembodiments, there is a seal coat between the semipermeable membrane andthe immediate release drug layer comprising drug for immediate release.

In certain embodiments, wet granulation comprises mixing of active drug,swellable hydrophilic polymer, and other excipients into a pre-blend,addition of liquid to the pre-blend for wetting of the pre-blend andformation of granules, milling for deagglomeration of granules, anddrying and screening of the resulting granules.

For water-sensitive drugs, wet granulation is performed using organicsolvents including methylene chloride, ethanol, isopropyl alcohol, butylalcohol, ethyl acetate, cyclohexane, and carbon tetrachloride. Incertain embodiments, wet granulation can be low shear, high shear, orfluid bed granulation. In certain embodiments, the fluid bed granulationcomprises top spray granulation or rotor granulation.

In certain embodiments, the programmable osmotic-controlled compositionsof the disclosure comprising active drugs with low drug loading, goodflow, and compressibility are made by dry granulation comprising rollercompaction or slugging. In such embodiments, it is important to matchparticle size of the drug and the swellable hydrophilic polymer, e.g.POLYOX®. In certain embodiments, compositions containing water-sensitiveactive drugs are made by a dry granulation process.

In certain embodiments, the dry granulation process includes slugging.In certain embodiments, slugging comprises blending of active drug andexcipients into a uniform blend, optional milling of the resulting blendto break down agglomerates and disperse the active drug, compacting theblend into large slugs, milling of the slugs into granules with desiredparticle size, and compressing the granules with extragranularexcipients into tablets.

In certain embodiments, dry granulation includes roller compaction,wherein densification of dry powder comprising active drug andexcipients into a compact is obtained by controlled feeding of thepowder through a set of directly opposed counter rotating rollers.

In certain embodiments, the disclosure provides making a multilayeredtablet core for providing delayed controlled release of a drug. Themultilayered tablet core comprises a push layer and a pull layer. Thepull layer comprises granules made by roller compaction or wetgranulation, and the push layer comprises granules made by directcompaction/slugging. In certain embodiments, the pull layer comprises anactive layer and a placebo layer.

In certain embodiments, the solvents used for coating the semipermeablemembrane include a mixture of acetone and water, wherein the filmporosity increases with increasing water content.

In certain embodiments, the programmable osmotic-controlled compositionsof the disclosure provide delayed extended release of methylphenidatehydrochloride. Such salt forms of methylphenidate are prone todegradation and often have stability and shelf-life problems. Additionof a stabilizing agent, e.g., a pH-adjusting agent, to the compositiondecreases undesired degradation and improves product stability. Incertain embodiments, the programmable osmotic-controlled methylphenidatecompositions of the disclosure include a stabilizing agent to minimizethe degradation of methylphenidate. In certain embodiments, thestabilizing agent comprises succinic acid, potassium phosphate, sodiumphosphate, fumaric acid, citric acid, tartaric acid, malic acid,hydrochloric acid, aspartic acid, glutamic acid, oxalic acid, lacticacid, malonic acid, glyceric acid, ascorbic acid, and any combinationthereof. In certain embodiments, methylphenidate hydrochloride is stablewithout the presence of a stabilizing agent.

7. EXAMPLES

The following examples illustrate the disclosure in a nonlimitingmanner. Unless indicated to the contrary, the numerical parameters setforth herein can vary depending upon the desired properties sought to beobtained by the present disclosure.

Example 1 Preparation of Delayed Release Methylphenidate TabletCompositions

The present Example provides various formulations for delayed releasemethylphenidate tablets as outlined in Table 1 and Table 2. Sixdifferent tablets were prepared.

TABLE 1 Tablet 1 Tablet 2 Tablet 3 Composition mg/dose mg/dose mg/dosePlacebo layer Polyethylene oxide (POLYOX ® N80) NA 75.00 NA Polyethyleneoxide (POLYOX ® 750) 75.00 NA 75.00 Povidone (KOLLIDON ® 30 LP) 8.008.00 8.00 Succinic acid 3.00 3.00 3.00 Stearic acid 0.90 0.90 0.90Butylated hydroxytoluene 0.10 0.10 0.10 Active layer 1 MethylphenidateHCl 10.80 10.80 NA Polyethylene oxide (POLYOX ® N80) 54.00 54.00 NAPovidone (KOLLIDON ® 30 LP) 4.00 4.00 NA Succinic acid 1.10 1.10 NAStearic acid 0.05 0.05 NA Butylated hydroxytoluene 0.05 0.05 NA Activelayer 2 Methylphenidate HCl 43.20 43.20 54.00 Polyethylene oxide(POLYOX ® N80) 149.0 149.0 207.0 Povidone (KOLLIDON ® 30 LP) 7.00 7.008.00 Succinic acid 3.00 3.00 3.00 Stearic acid 0.75 0.75 0.90 Butylatedhydroxytoluene 0.05 0.05 0.10 Push Layer Polyethylene oxide (POLYOX ®303) 135.0 135.0 135.0 Povidone (KOLLIDON ® 30 LP) 36.50 36.50 36.50Sodium chloride 9.15 9.15 9.15 Stearic acid 0.45 0.45 0.45 Butylatedhydroxytoluene 0.10 0.10 0.10 Red pigment blend 1.80 1.80 1.80Functional Coating Layer Cellulose acetate 40.70 40.70 40.70Polyethylene glycol 3350 0.40 0.40 0.40 Acetone* NA NA NA Purifiedwater* NA NA NA Total Weight 583.70 583.70 583.70 *Removed duringprocess

TABLE 2 Tablet 4 Tablet 5 Tablet 6 Composition mg/dose mg/dose mg/dosePlacebo layer Polyethylene oxide (POLYOX ® N80) NA 75.00 NA Polyethyleneoxide (POLYOX ® 750) 75.00 NA 75.00 Povidone (KOLLIDON ® 30 LP) 8.008.00 8.00 Succinic acid 3.00 3.00 3.00 Stearic acid 0.90 0.90 0.90Butylated hydroxytoluene 0.10 0.10 0.10 Active layer 1 MethylphenidateHCl 10.80 10.80 NA Polyethylene oxide (POLYOX ® N80) 37.24 37.24 NAPovidone (KOLLIDON ® 30 LP) 4.00 4.00 NA Succinic acid 1.10 1.10 NAStearic acid 0.05 0.05 NA Butylated hydroxytoluene 0.05 0.05 NA Activelayer 2 Methylphenidate HCl 43.20 43.20 54.0 Polyethylene oxide(POLYOX ® N80) 216.0 216.0 270.0 Povidone (KOLLIDON ® 30 LP) 7.0 7.0 8.0Succinic acid 3.0 3.0 3.0 Stearic acid 0.75 0.75 0.90 Butylatedhydroxytoluene 0.05 0.05 0.10 Push Layer Polyethylene oxide (POLYOX ®303) 135.0 135.0 135.0 Povidone (KOLLIDON ® 30 LP) 36.50 36.50 36.50Sodium chloride 9.15 9.15 9.15 Stearic acid 0.45 0.45 0.45 Butylatedhydroxytoluene 0.10 0.10 0.10 Red pigment blend 1.80 1.80 1.80Functional Coating Layer Cellulose acetate 40.70 40.70 40.70Polyethylene glycol 3350 0.40 0.40 0.40 Acetone* NA NA NA Purifiedwater* NA NA NA Total Weight 687.58 687.58 647.1 *Removed during process

Tablets 1, 2, 4, and 5 contain two active layers, whereas Tablet 3 andTablet 6 contain only one active layer. Tablets 1 and 2, and Tablets 4and 5, differ in the grades of POLYOX® in the placebo layer. The tabletswere made according to the following manufacturing procedure.

Manufacturing Procedure:

Tablets 1-6 comprise two active layers, Active layer 1 and Active layer2, to provide chrono drug release or extended release with increasingdrug concentration. Separate blends of placebo layer, Active layer 1,Active layer 2, and push layer were made as per Tablets 1-6.

-   1. Preparation of placebo blend: Povidone and BHT were added to    dehydrated alcohol in a suitable stainless steel container and mixed    to obtain a clear solution; the resulting solution was sprayed onto    polyethylene oxide taken in a high shear mixer; the resulting    granules were dried at about 40° C. in a forced air oven, and    screened through screen #20; the resulting screened granules were    taken in a V-blender containing succinic acid (prescreened through    screen #30) and mixed for about 7 minutes at 25 RPM, followed by    addition of stearic acid (prescreened through screen #30) and mixed    for about 3 minutes at 25 RPM.-   2. Preparation of active layer 1 and active layer 2 blend: Povidone    and BHT were added to dehydrated alcohol in a suitable stainless    steel container and mixed to obtain a clear solution; the resulting    solution was sprayed onto a blend of methylphenidate and    polyethylene oxide taken in a high shear mixer; the resulting    granules were dried at about 40° C. in a forced air oven, and    screened through screen #20; the resulting screened granules were    taken in a V-blender containing succinic acid (prescreened through    screen #30) and mixed for about 7 minutes at 25 RPM, followed by    addition of stearic acid (prescreened through screen #30) and mixed    for about 3 minutes at 25 RPM.-   3. Preparation of push layer blend: Povidone and BHT were added to    dehydrated alcohol in a suitable stainless steel container and mixed    to obtain a clear solution; the resulting solution was sprayed onto    a blend of polyethylene oxide, sodium chloride, and red pigment    blend taken in a high shear mixer; the resulting granules were dried    at about 40° C. in a forced air oven, and screened through screen    #20; the resulting screened granules were taken in a V-blender    containing stearic acid (prescreened through screen #30) and mixed    for about 3 minutes at 25 RPM.-   4. Required amount of each blend (as per Tablets 1-3) was filled    into the die and then compressed into tetra-layer tablet    compositions.-   5. Cellulose acetate was added to a stainless steel container    charged with acetone and mixed to obtain a clear solution.-   6. Polyethylene glycol 3350 was added to the solution from step #5,    followed by the addition of water, and mixed for about 30 minutes.-   7. The tablets from step #4 were taken in a coating pan and coated    with the solution from step #6 until the target % weight gain is    attained, and then cured at a product temperature of 40° C. for one    hour.-   8. A hole of about 0.3 mm is drilled into the coating at the center    of the placebo end of the tablet.

Example 2 Preparation of Composition Providing IR of Clonidine andDelayed Release of Methylphenidate

The present Example provides various formulations for delayed releasemethylphenidate tablets that comprise clonidine HCl IR coating. Thecomponents of the clonidine HCl IR coating are provided in Table 3below.

TABLE 3 Clonidine HCl IR coating Tablets 7-12 Composition mg/doseClonidine HCl 0.3 Hypromellose (METHOCEL ™ E5 LV) 2.5 Talc 0.5 Ethanol*NA Purified water* NA *Removed during process

The Clonidine HCl IR coating is added to Tablets 1-6 of the Example 1according to the procedure detailed below.

Manufacturing Procedure:

-   1. Hypromellose is added to ethanol taken in a stainless steel    container and mixed until it is uniformly dispersed. Purified water    is slowly added and mixed until a clear solution is formed.-   2. To the solution from step #1, clonidine HCl is added and mixed    until dissolved.-   3. Talc is added to the solution from step #2 and mixed until it is    uniformly dispersed.-   4. Methylphenidate HCl tablets (Tablets 1-6) are taken in a coating    pan and coated with the dispersion from step #3.

Example 3 Preparation of Delayed Release Amphetamine Tablet Compositions

The present Example provides three different delayed release amphetaminetablet compositions. The components of the different tablets areoutlined below in Table 4.

TABLE 4 Tablet 13 Tablet 14 Tablet 15 Composition mg/dose mg/dosemg/dose Placebo Layer Polyethylene oxide NA 6.750 NA (POLYOX ® N80)Polyethylene oxide 6.750 NA 6.750 (POLYOX ® 750) Povidone (KOLLIDON ® 30LP) 0.720 0.720 0.720 Succinic acid 0.270 0.270 0.270 Stearic acid 0.0810.081 0.081 Butylated hydroxytoluene 0.009 0.009 0.009 Active Layer 1Mixed amphetamine salts 1.000 1.000 NA (base equivalence) Polyethyleneoxide 3.35 3.35 NA (POLYOX ® N80) Povidone (KOLLIDON ® 30 LP) 0.3600.360 NA Succinic acid 0.099 0.099 NA Stearic acid 0.004 0.004 NAButylated hydroxytoluene 0.0045 0.0045 NA Active Layer 2 Mixedamphetamine salts (base 4.000 4.000 5.000 equivalence) Polyethyleneoxide 19.44 19.44 24.3 (POLYOX ® N80) Povidone (KOLLIDON ® 30 LP) 0.6300.630 0.720 Succinic acid 0.270 0.270 0.270 Stearic acid 0.0675 0.06750.081 Butylated hydroxytoluene 0.0045 0.0045 0.009 Push LayerPolyethylene oxide 12.150 12.150 12.150 (POLYOX ® 303) Povidone(KOLLIDON ® 3.285 3.285 3.285 30 LP) Sodium chloride 0.823 0.823 0.823Stearic acid 0.45 0.45 0.45 Butylated hydroxytoluene 0.0405 0.04050.0405 Red pigment blend 0.162 0.162 0.162 Functional Coating LayerCellulose acetate 3.663 3.663 3.663 Polyethylene glycol 3350 0.036 0.0360.036 Acetone* NA NA NA Purified water* NA NA NA Total Weight 53.14953.149 53.149 *Removed during process

Tablet 13 and Tablet 14 differ in the grades of POLYOX® in the placebolayer. Both Tablet 13 and Tablet 14 include two active layers, whereasTablet 15 includes one active layer. The tablets are made according tothe following manufacturing procedure.

Manufacturing Procedure:

Separate blends of placebo layer, active layer 1, active layer 2, andpush layer are made as per Tablets 13-15.

-   1. Preparation of placebo blend: Povidone and BHT are added to    dehydrated alcohol in a suitable stainless steel container and mixed    to obtain a clear solution; the resulting solution is sprayed onto    polyethylene oxide taken in a high shear mixer; the resulting    granules are dried at about 40° C. in a forced air oven, and    screened through screen #20; the resulting screened granules were    taken in a V-blender containing succinic acid (prescreened through    screen #30) and mixed for about 7 minutes at 25 RPM, followed by    addition of stearic acid (prescreened through screen #30) and mixed    for about 3 minutes at 25 RPM.-   2. Preparation of active layer 1 and active layer 2 blend: Povidone    and BHT are added to dehydrated alcohol in a suitable stainless    steel container and mixed to obtain a clear solution; the resulting    solution is sprayed onto a blend of mixed amphetamine base, and    polyethylene oxide taken in a high shear mixer; the resulting    granules are dried at about 40° C. in a forced air oven, and    screened through screen #20; the resulting screened granules are    taken in a V-blender containing succinic acid (prescreened through    screen #30) and mixed for 7 minutes at 25 RPM, followed by addition    of stearic acid (prescreened through screen #30) and mixed for about    3 minutes at 25 RPM.-   3. Preparation of push layer blend: Povidone and BHT are added to    dehydrated alcohol in a suitable stainless steel container and mixed    to obtain a clear solution; the resulting solution is sprayed onto a    blend of polyethylene oxide, sodium chloride, and red pigment blend    taken in a high shear mixer; the resulting granules are dried at    about 40° C. in a forced air oven, and screened through screen #20;    the resulting screened granules are taken in a V-blender containing    stearic acid (prescreened through screen #30) and mixed for about 3    minutes at 25 RPM.-   4. Required amount of each blend (as per Tablets 13-15) is filled    into the die and then compressed as tetra-layer tablet compositions.-   5. Cellulose acetate is added to a stainless steel container charged    with acetone and mixed to obtain a clear solution.-   6. Polyethylene glycol 3350 is added to the solution from step #5,    followed by the addition of water, and mixed for about 30 minutes.-   7. The tablets from step #4 are taken in a coating pan and coated    with the solution from step #6 until the target % weight gain is    attained and then cured at a product temperature of about 40° C. for    one hour.-   8. A hole of about 0.3 mm is drilled into the coating at the center    of placebo end of the tablet.

Example 4 Preparation of Pulsatile Release Methylphenidate HCl

The present Example provides a formulation for pulsatile releasemethylphenidate HCl tablet. The components of the tablet are outlinedbelow in Table 5.

TABLE 5 Tablet 16 Composition mg/dose Placebo Layer Polyethylene oxide75.00 (POLYOX ® N80) Povidone (KOLLIDON ® 30 8.00 LP) Stearic acid 0.90Butylated hydroxytoluene 0.10 Active Layer 1 Methylphenidate HCl 27.00Polyethylene oxide 81.00 (POLYOX ® N80) Povidone (KOLLIDON ® 30 4.00 LP)Stearic acid 0.05 Butylated hydroxytoluene 0.05 Placebo LayerPolyethylene oxide 75.00 (POLYOX ® N80) Povidone (KOLLIDON ® 30 8.00 LP)Stearic acid 0.90 Butylated hydroxytoluene 0.10 Active Layer 2Methylphenidate HCl 27.00 Polyethylene oxide 81.0 (POLYOX ® N80)Povidone (KOLLIDON ® 30 4.00 LP) Stearic acid 0.05 Butylatedhydroxytoluene 0.05 Push Layer Polyethylene oxide 135.0 (POLYOX ® 303)Povidone (KOLLIDON ® 30 36.50 LP) Sodium chloride 9.15 Stearic acid 0.45Butylated hydroxytoluene 0.10 Red pigment blend 1.80 Functional CoatingLayer Cellulose acetate 40.70 Polyethylene glycol 3350 0.40 Acetone* NAPurified water* NA Total Weight 616.30 *Removed during Process

Tablet 16 contains two placebo layers and two active layers disposedalternately. The composition further includes a push layer and afunctional coating layer. Tablet 16 is made according to the proceduredetailed below.

Manufacturing Procedure:

Separate blends of placebo layer, active layer 1, active layer 2, andpush layer are made as per Tablet 16.

-   1. Preparation of placebo blend: Povidone and BHT are added to    dehydrated alcohol in a suitable stainless steel container and mixed    to obtain a clear solution; the resulting solution is sprayed onto    polyethylene oxide taken in a high shear mixer; the resulting    granules are dried at about 40° C. in a forced air oven, and    screened through screen #20; the resulting screened granules are    taken in a V-blender containing stearic acid (prescreened through    screen #30) and mixed for about 3 minutes at 25 RPM.-   2. Preparation of active layer 1 and active layer 2 blend: Povidone    and BHT are added to dehydrated alcohol in a suitable stainless    steel container and mixed to obtain a clear solution; the resulting    solution is sprayed onto a blend of methylphenidate, and    polyethylene oxide taken in a high shear mixer; the resulting    granules are dried at about 40° C. in a forced air oven, and    screened through screen #20; the resulting screened granules are    taken in a V-blender containing stearic acid (prescreened through    screen #30) and mixed for about 3 minutes at 25 RPM.-   3. Preparation of push layer blend: Povidone and BHT are added to    dehydrated alcohol in a suitable stainless steel container and mixed    to obtain a clear solution; the resulting solution is sprayed onto a    blend of polyethylene oxide, sodium chloride, and red pigment blend    taken in a high shear mixer; the resulting granules are dried at    about 40° C. in a forced air oven, and screened through screen #20;    the resulting screened granules are taken in a V-blender containing    stearic acid (prescreened through screen #30) and mixed for about 3    minutes at 25 RPM.-   4. Required amount of each blend (as per Tablet 16) is filled into    the die and then compressed into penta-layer tablet compositions.-   5. Cellulose acetate is added to a stainless steel container charged    with acetone and mixed to obtain a clear solution.-   6. Polyethylene glycol 3350 is added to the solution from step #5,    followed by the addition of water, and mixed for about 30 minutes.-   7. The tablets from step #4 are taken in a coating pan and coated    with the solution from step #6 until the target % weight gain is    attained and then cured at a product temperature of about 40° C. for    one hour.-   8. A hole of about 0.3 mm is drilled into the coating at the center    of placebo end of the tablet.

Clonidine HCl IR Coating

The present Example provides a formulation for pulsatile releasemethylphenidate HCl tablet that comprises clonidine HCl IR coating. Thecomponents of the clonidine HCl IR coating are provided in Table 6below.

TABLE 6 Tablet 17 Composition mg/dose Clonidine Hydrochloride 0.3Hypromellose (METHOCEL E5LV) 2.5 Talc 0.5 Ethanol* NA Purified water* NA*Removed during Process

The clonidine HCl IR coating is added to Tablet 16 of the Example 4according to the procedure detailed below.

Manufacturing Procedure:

-   1. Hypromellose is added to ethanol taken in a stainless steel    container and mixed until it is uniformly dispersed. Purified water    is slowly added and mixed until a clear solution is formed.-   2. To the solution from step # 1, clonidine hydrochloride is added    and mixed until dissolved.-   3. Talc is added to the solution from step # 2 and mixed until it is    uniformly dispersed.-   4. The methylphenidate HCl tablets (Tablet 16) are taken in a    coating pan and coated with the dispersion from step # 3.

Example 5 Preparation of Delayed Release Methylphenidate TabletCompositions

The present Example provides two different delayed releasemethylphenidate tablet compositions. The components of the differenttablets are outlined below in Table 7.

TABLE 7 Tablet 18 Tablet 19 Composition mg/dose mg/dose Placebo LayerPolyethylene oxide (POLYOX ® 100.31 100.31 WSR 1105) Povidone(KOLLIDON ® 30 LP) 5.22 5.22 Stearic acid 1.00 1.00 Butylatedhydroxytoluene 0.13 0.13 Red pigment blend 0.07 0.07 Cab-O-Sil ® (fumedsilica) 0.27 0.27 Dehydrated alcohol* q.s. q.s. Active LayerMethylphenidate HCl 54.00 54.00 Polyethylene oxide (POLYOX ® N80) 81.0081.00 Sodium chloride 10.00 10.00 Povidone (KOLLIDON ® 30 LP) 7.60 7.60Stearic acid 0.90 0.90 Butylated hydroxytoluene 0.10 0.10 Dehydratedalcohol* q.s. q.s. Push Layer Polyethylene oxide (POLYOX ® 88.00 88.00WSR 303) Sodium chloride 22.00 22.00 Povidone (KOLLIDON ® 30 LP) 11.5011.50 Stearic acid 0.50 0.50 Butylated hydroxytoluene (BHT) 0.20 0.20Red pigment blend 1.50 1.50 Cab-O-Sil ® 0.30 0.30 Dehydrated alcohol*q.s. q.s. Total Core Weight 385.00 385.00 Functional Coating LayerOPADRY ® CA clear (95:5) 48.13 57.75 Total Tablet Weight 433.13 442.75*Removed during process

Tablet 18 and Tablet 19 include different amounts of OPADRY® CA withCA:PEG ratio of about 95:5. The tablets were made according to thefollowing manufacturing procedure.

Manufacturing Procedure

Separate blends of placebo layer, drug layer, and push layer were madeas per Tablets 18 and 19.

-   1. Preparation of placebo blend: Povidone and BHT were added to    dehydrated alcohol in a suitable stainless steel container and mixed    to obtain a clear solution; the resulting solution was sprayed on to    a blend of polyethylene oxide and red pigment blend taken in a high    shear mixer; the resulting granules were dried at about 40° C. in a    forced air oven, and screened through screen #20; the resulting    screened granules were taken in a V-blender containing Cab-O-Sil®    (prescreened through screen #30) and mixed for about 5 minutes at 25    RPM, followed by addition of stearic acid and mixed for about 3    minutes.-   2. Preparation of active layer blend: Povidone and BHT were added to    dehydrated alcohol in a suitable stainless steel container and mixed    to obtain a clear solution; the resulting solution was sprayed on to    a blend of methylphenidate, polyethylene oxide and sodium chloride    taken in a high shear mixer; the resulting granules were dried at    about 40° C. in a forced air oven, and screened through screen #20;    the resulting screened granules are taken in a V-blender containing    stearic acid (prescreened through screen #30) and mixed for about 3    minutes at 25 RPM.-   3. Preparation of push layer blend: Povidone and BHT were added to    dehydrated alcohol in a suitable stainless steel container and mixed    to obtain a clear solution; the resulting solution was sprayed on to    a blend of polyethylene oxide, sodium chloride, and red pigment    blend taken in a high shear mixer; the resulting granules were dried    at about 40° C. in a forced air oven, and screened through screen    #20; the resulting screened granules were taken in a V-blender    containing Cab-O-Sil® (prescreened through screen #30) and mixed for    about 5 minutes at 25 RPM, followed by addition of stearic acid and    mixed for about 3 minutes.-   4. Required amount of each blend (as per Tablets 18 and 19) was    filled into the die and then compressed as tri-layer tablet    composition.-   5. OPADRY® CA was added to a stainless steel container charged with    acetone and water (about 92:8) and mixed for not less than about 60    minutes to obtain a clear solution.-   6. The tablets from step #4 were taken in a coating pan and coated    with the solution from step #5 until the target % weight gain was    obtained and cured at a product temperature of about 40° C. for one    hour.-   7. A hole of about 0.3 mm was drilled into the coating at the center    of placebo end of the tablet.

Example 6 Effect of POLYOX Amount Present in Placebo Layer on ReleaseRate Profile of the Composition

The present Example provides two different delayed releasemethylphenidate tablets with various amounts of POLYOX® in the placebolayer. The components of the two tablets are outlined below in Table 8.

TABLE 8 Tablet 20 Tablet 21 Composition mg/dose mg/dose Placebo LayerPolyethylene oxide (POLYOX ® WSR 150.0 75.0 1105) Povidone (KOLLIDON ®30 LP) 8.0 4.0 Stearic acid 1.6 0.8 Butylated hydroxytoluene 0.20 0.10Dehydrated alcohol* q.s. q.s. Active Layer Methylphenidate HCl 54.0 54.0Polyethylene oxide (POLYOX ® N80) 135.0 135.0 Povidone (KOLLIDON ® 30LP) 4.0 4.0 Stearic acid 0.90 0.90 Butylated hydroxytoluene 0.10 0.10Dehydrated alcohol* q.s. q.s. Push Layer Polyethylene oxide (POLYOX ®WSR 303) 88.00 88.00 Sodium chloride 22.00 22.00 Povidone (KOLLIDON ® 30LP) 12.0 12.0 Stearic acid 0.50 0.50 Butylated hydroxytoluene (BHT) 0.200.20 Red pigment blend 1.50 1.50 Dehydrated alcohol* q.s. q.s. TotalCore Weight 478.0 398.0 Functional Coating Layer OPADRY ® CA clear(95:5) 71.7 59.7 Total Weight 549.7 457.7 *Removed during process

Trilayer methylphenidate tablets were made according to the procedure asper Example 5. Tablets 20 and 21 were tested for dissolution in about900 ml of about 0.01N HCl for up to 24 hours, using USP Apparatus II(Sinkers), with agitation at 50 rpm and 37° C. Percentage dissolution ofthe tablets was measured at 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, and24 hours. FIG. 7 shows the effect of POLYOX® amount present in placebolayer on dissolution rate of the tablet. The Figure demonstrates thatdissolution rate of the tablet is improved with increasing the amount ofPOLYOX® in the placebo layer. The Figure further demonstrates that thetablet, with placebo layer containing POLYOX® 1105, does not show anychange in lag time with increasing POLYOX® amount in placebo layer.

Example 7 Effect of Average Molecular Weight of POLYOX Present inPlacebo Layer on Lag Time, Release Rate, and Drug Recovery

The present Example provides two delayed release methylphenidate tabletscomprising different grades of POLYOX® in the placebo layer. Thecomponents of the two tablets are outlined below in Table 9.

TABLE 9 Tablet 22 Tablet 20 Composition mg/dose mg/dose Placebo LayerPolyethylene oxide (POLYOX ® 205) 150.0 — Polyethylene oxide (POLYOX ®1105) 150.0 Povidone (KOLLIDON ® 30 LP) 8.0 8.0 Stearic acid 1.6 1.6Butylated hydroxytoluene 0.20 0.10 Dehydrated alcohol* q.s. q.s. ActiveLayer Methylphenidate HCl 54.0 54.0 Polyethylene oxide (POLYOX ® N80)135.0 135.0 Povidone (KOLLIDON ® 30 LP) 4.0 4.0 Stearic acid 0.90 0.90Butylated hydroxytoluene 0.10 0.10 Dehydrated alcohol* q.s. q.s. PushLayer Polyethylene oxide (POLYOX ® WSR 303) 88.00 88.00 Sodium chloride22.00 22.00 Povidone (KOLLIDON ® 30 LP) 12.0 12.0 Stearic acid 0.50 0.50Butylated hydroxytoluene (BHT) 0.20 0.20 Red pigment blend 1.50 1.50Dehydrated alcohol* q.s. q.s. Total Core Weight 478.0 478.0 FunctionalCoating Layer OPADRY ® CA clear (95:5) 71.7 71.7 Total Weight 549.7549.7 *Removed during processTrilayer methylphenidate tablets were made according to the procedure asper Example 5. Tablets 20 and 22 were tested for dissolution in about900 ml of about 0.01N HCl for up to 24 hours, using USP Apparatus II(Sinkers), with agitation at 50 rpm and 37° C.

Percentage dissolution of the tablets was measured at 2, 4, 6, 8, 10,12, 14, 16, 18, 20, 22, and 24 hours. FIG. 8 shows the effect of averagemolecular weight of the POLYOX®, present in the placebo layer, ondissolution rate of the tablet. The Figure demonstrates an improvementin dissolution rate and reduction in drug recovery, with no change inlag time, with increasing the average molecular weight of POLYOX®,present in the placebo layer, from about 600K (POLYOX® 205) to about900K (POLYOX® 1105).

Example 8 Effect of Drug to Polymer Ratio in the Active Layer on LagTime of the Dosage Form

The present Example provides two delayed release methylphenidate tabletscomprising active layers with varying drug to polymer ratios. Thecomponents of the two tablets are outlined below in Table 10.

TABLE 10 Tablet 23 Tablet 24 Composition mg/dose mg/dose Placebo LayerPolyethylene oxide (POLYOX ® 150.0 150.0 WSR 1105) Povidone (KOLLIDON ®30 LP) 8.0 8.0 Stearic acid 1.6 1.6 Butylated hydroxytoluene 0.20 0.20Dehydrated alcohol* q.s. q.s. Active Layer Methylphenidate HCl 54.0 54.0Polyethylene oxide (POLYOX ® N80) 207.0 (20:80) 135.0 (28:72) Povidone(KOLLIDON ® 30 LP) 4.0 4.0 Stearic acid 0.9 0.9 Butylated hydroxytoluene0.10 0.10 Dehydrated alcohol* q.s. q.s. Push Layer Polyethylene oxide(POLYOX ® 98.00 98.00 WSR 303) Sodium chloride 12.00 12.00 Povidone(KOLLIDON ® 30 LP) 12.0 12.0 Stearic acid 0.50 0.50 Butylatedhydroxytoluene (BHT) 0.20 0.20 Red pigment blend 1.50 1.50 Dehydratedalcohol* q.s. q.s. Total core Weight 550.0 478.0 Functional CoatingLayer OPADRY ® CA clear (95:5) 82.5 71.7 Total Weight 632.5 549.7*Removed during process

Trilayer methylphenidate tablets were made according to the procedure asper Example 5. Tablets 23 and 24 were tested for dissolution in about900 ml of about 0.01N HCl for up to 24 hours, using USP Apparatus II(Sinkers), with agitation at 50 rpm and 37° C. Percentage dissolution ofthe tablets was measured at 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, and24 hours. FIG. 9 shows the effect of drug to polymer ratio in the activelayer on lag time of the tablet. The Figure demonstrates that a drug topolymer ratio of about 28:72 provides a lag time of about 9 hours and adrug to polymer ratio of 20:80 provides a lag time of about 10 hours.

Example 9 Effect of Sodium Chloride Amount in the Active Layer on DrugRecovery

The present Example provides two delayed release methylphenidatetablets. Tablet 25 contains sodium chloride in the active layer, whereasTablet 26 does not. The components of the two tablets are outlined belowin Table 11.

TABLE 11 Tablet 25 Tablet 26 Composition mg/dose mg/dose Placebo LayerPolyethylene oxide (POLYOX ® WSR 1105) 150.0 150.0 Povidone (KOLLIDON ®30 LP) 8.0 8.0 Stearic acid 1.6 1.6 Butylated hydroxytoluene 0.20 0.20Dehydrated alcohol* q.s. q.s. Active Layer Methylphenidate HCl 54.0 54.0Polyethylene oxide (POLYOX ® N80) 125.0 135.0 Sodium chloride 10.0 —Povidone (KOLLIDON ® 30 LP) 4.0 4.0 Stearic acid 0.9 0.9 Butylatedhydroxytoluene 0.10 0.10 Dehydrated alcohol* q.s. q.s. Push LayerPolyethylene oxide (POLYOX ® WSR 303) 98.00 98.00 Sodium chloride 22.0022.00 Povidone (KOLLIDON ® 30 LP) 12.0 12.0 Stearic acid 0.50 0.50Butylated hydroxytoluene (BHT) 0.20 0.20 Red pigment blend 1.50 1.50Dehydrated alcohol* q.s. q.s. Total Core Weight 478.0 478.0 FunctionalCoating Layer OPADRY ® CA clear (95:5) 71.7 71.7 Total Weight 549.7549.7 *Removed during processTrilayer methylphenidate tablets were made according to the procedure asper Example 5. Tablets 25 and 26 were tested for dissolution in about900 ml of about 0.01N HCl for up to 24 hours, using USP Apparatus II(Sinkers), with agitation at 50 rpm and 37° C. Percentage dissolution ofthe tablets was measured at 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, and24 hours. FIG. 10 compares drug recovery from tablets with and withoutsodium chloride in drug layer. The Figure demonstrates that presence ofsodium chloride in active layer improves drug recovery by about 5%, incomparison to tablets without sodium chloride in drug layer.

Example 10 Effect of Sodium Chloride Amount in the Push Layer on DrugRecovery

The present Example provides four delayed release methylphenidatetablets comprising various amounts of sodium chloride in the push layer.The components of the two tablets are outlined below in Table 12.

TABLE 12 Tablet 24 Tablet 27 Tablet 28 Tablet 29 Composition mg/dosemg/dose mg/dose mg/dose Placebo Layer Polyethylene oxide 150.0 150.0150.0 150.0 (POLYOX ® WSR 1105) Povidone (KOLLIDON ® 8.0 8.0 8.0 8.0 30LP) Stearic acid 1.6 1.6 1.6 1.6 Butylated 0.20 0.20 0.2 0.2hydroxytoluene Dehydrated alcohol* q.s. q.s. q.s. q.s. Active LayerMethylphenidate HCl 54.0 54.0 54.0 54.0 Polyethylene oxide 135.0 135.0135.0 135.0 (POLYOX ® N80) Povidone (KOLLIDON ® 4.0 4.0 4.0 4.0 30 LP)Stearic acid 0.9 0.9 0.9 0.9 Butylated 0.10 0.10 0.10 0.10hydroxytoluene Dehydrated alcohol* q.s. q.s. q.s. q.s. Push LayerPolyethylene oxide 98.00 80.00 88.0 110.0 (POLYOX ® WSR 303) Sodiumchloride 12.00 30.00 22.0 NA Povidone (KOLLIDON ® 12.0 12.0 12.0 12.0 30LP) Stearic acid 0.50 0.50 0.50 0.50 Butylated 0.20 0.20 0.20 0.20hydroxytoluene (BHT) Red pigment blend 1.50 1.50 1.50 1.50 Dehydratedalcohol* q.s. q.s. q.s. q.s. Total Core Weight 478.0 478.0 478.0 478.0Functional Coating Layer OPADRY ® CA clear 71.7 71.7 71.7 71.7 TotalWeight 549.7 549.7 549.7 549.7 *Removed during process

Trilayer methylphenidate tablets were made according to the procedure asper Example 5. Tablets 24, 27, 28, and 29, were tested for dissolutionin about 900 ml of about 0.01N HCl for up to 24 hours, using USPApparatus II (Sinkers), with agitation at 50 rpm and 37° C. Percentagedissolution of the tablets was measured at 2, 4, 6, 8, 10, 12, 14, 16,18, 20, 22, and 24 hours. FIG. 11 shows the effect of sodium chloride inpush layer on drug recovery from the tablet. The Figure demonstratesthat presence of sodium chloride in push layer improves release rate anddrug recovery at 24 hours. The Figure further demonstrates thatincreasing the amount of sodium chloride in the push layer improvesrelease rate and drug recovery at 24 hours.

Example 11 Effect of Membrane Composition on Lag Time and Drug Recovery

The present Example provides two delayed release methylphenidatetablets. Tablet 30 contains OPADRY® CA with CA:PEG ratio of about 95:5in the functional coating layer, while Tablet 31 contains OPADRY® CAwith CA:PEG ratio of about 98:2 in the functional coating layer. Thecomponents of the two tablets are outlined below in Table 13.

TABLE 13 Tablet 30 Tablet 31 Composition mg/dose mg/dose Placebo LayerPolyethylene oxide (POLYOX ® N205) 150.0 150.0 Povidone (KOLLIDON ® 30LP) 8.0 8.0 Stearic acid 1.6 1.6 Butylated hydroxytoluene 0.20 0.20Dehydrated alcohol* q.s. q.s. Active Layer Methylphenidate HCl 54.0 54.0Polyethylene oxide (POLYOX ® N80) 135.0 135.0 Povidone (KOLLIDON ® 30LP) 4.0 4.0 Stearic acid 0.9 0.9 Butylated hydroxytoluene 0.10 0.10Dehydrated alcohol* q.s. q.s. Push Layer Polyethylene oxide (POLYOX ®WSR 303) 80.00 80.00 Sodium chloride 30.00 30.00 Povidone (KOLLIDON ® 30LP) 12.0 12.0 Stearic acid 0.50 0.50 Butylated hydroxytoluene (BHT) 0.200.20 Red pigment blend 1.50 1.50 Dehydrated alcohol* q.s. q.s. CoreTablet Weight 478.0 478.0 Functional Coated Layer OPADRY ® CA clear 71.771.7 CA:PEG Ratio 95:5 98:2 Total Weight 549.7 549.7 *Removed duringprocessTrilayer methylphenidate tablets were made according to the proceduredescribed as per Example 5. Tablets 30 and 31 were tested fordissolution in about 900 ml of about 0.01N HCl for up to 24 hours, usingUSP Apparatus II (Sinkers), with agitation at 50 rpm and 37° C.Percentage dissolution of the tablets was measured at 2, 4, 6, 8, 10,12, 14, 16, 18, 20, 22, and 24 hours. FIG. 12 shows effect of CA to PEGratio in the membrane on lag time and drug recovery of the tablets with15% coating weight gain of the membrane. The Figure demonstrates thatincreasing amount of cellulose acetate in the membrane increases lagtime and reduces drug recovery from the membrane coated tablets.

Example 12 Effect of Coating Level and Presence of Sodium Chloride inActive Layer on Lag Time and Drug Recovery

The present Example provides four delayed release methylphenidatetablets. Tablets 32 and 32A include sodium chloride in the active layerand Tablets 33 and 34 do not. Tablets 32 and 32A differ in the amount ofOPADRY® CA clear (95:5) in the functional coating layer. Tablet 32comprises a 15% coating weight gain of the functional coat layer andTablet 32A comprises a 17.5% coating weight gain of the functional coatlayer. The components of the four tablets are outlined below in Table14.

TABLE 14 Tablet Tablet Tablet Tablet 32 33 34 32A Composition mg/dosemg/dose mg/dose mg/dose Placebo Layer Polyethylene oxide 150.0 150.075.0 150.0 (POLYOX ® N205) Povidone (KOLLIDON ® 8.0 8.0 4.0 8.0 30 LP)Stearic acid 1.6 1.6 0.8 1.6 Butylated hydroxytoluene 0.20 0.20 0.1 0.2Dehydrated alcohol* q.s. q.s. q.s. Active Layer Methylphenidate HCl 54.054.0 54.0 54.0 Polyethylene oxide 125.0 135.0 135.0 125.0 (POLYOX ® N80)Povidone (KOLLIDON ® 4.0 4.0 4.0 4.0 30 LP) Stearic acid 0.9 0.9 0.9 0.9Sodium chloride 10.0 NA NA 10.0 Butylated hydroxytoluene 0.10 0.10 0.10.10 Dehydrated alcohol* q.s. q.s. q.s. q.s. Push Layer Polyethyleneoxide 88.0 88.0 88.0 88.0 (POLYOX ® WSR 303) Sodium chloride 22.0 22.022.0 22.0 Povidone (KOLLIDON ® 12.0 12.0 12.0 12.0 30 LP) Stearic acid0.50 0.50 0.50 0.50 Butylated hydroxytoluene 0.20 0.20 0.20 0.20 (BHT)Red pigment blend 1.50 1.50 1.5 1.5 Dehydrated alcohol* q.s. q.s. q.s.q.s. Core Tablet Weight 478.0 478.0 398.0 478.0 Functional Coating LayerOPADRY ® CA clear (95:5) 71.7 71.7 59.7 83.65 Total Weight 549.0 549.0457.7 561.65 *Removed during processTrilayer methylphenidate tablets were made according to the procedure asper Example 5. Tablets 32, 32A, the 33, and 34 were tested fordissolution in about 900 ml of about 0.01N HCl for up to 24 hours, usingUSP Apparatus II (Sinkers), with agitation at 50 rpm and 37° C.Percentage dissolution of the tablets was measured at 2, 4, 6, 8, 10,12, 14, 16, 18, 20, 22, and 24 hours. FIG. 13 shows effect of coatingweight gain/coating level of the semipermeable membrane on drug recoveryand lag time. The Figure demonstrates that the tablet with a highercoating level (Tablet 32A) exhibits reduced drug recovery and increasedlag time. The Figure further compares drug recovery between coatedtablets with and without sodium chloride in active layer. The Figuredemonstrates that tablets containing sodium chloride in active layerexhibit improved drug recovery. The Figure further shows that a decreasein amount of polyethylene oxide polymer in placebo layer improves drugrecovery.

Example 13 Effect of Presence of Sodium Chloride in Active Layer on LagTime and Drug Recovery

The present Example provides three delayed release methylphenidatetablets comprising different amounts of sodium chloride in the activelayer and/or different grades of POLYOX® in the placebo layer. Thecomponents of the three tablets are outlined below in Table 15.

TABLE 15 Tablet 35 Tablet 36 Tablet 37 Composition mg/dose mg/dosemg/dose Placebo Layer Polyethylene oxide (POLYOX ® 150.0 150.0 — N205)Polyethylene oxide (POLYOX ® — — 150.0 1105) Povidone (KOLLIDON ® 30 LP)8.0 8.0 8.0 Stearic acid 1.6 1.6 1.6 Butylated hydroxytoluene 0.20 0.200.2 Dehydrated alcohol* q.s. q.s. q.s. Active Layer Methylphenidate HCl54.0 54.0 54.0 Polyethylene oxide (POLYOX ® 187.0 197.0 125.0 N80)Povidone (KOLLIDON ® 30 LP) 4.0 4.0 4.0 Stearic acid 0.9 0.9 0.9 Sodiumchloride 20.0 10.0 10.0 Butylated hydroxytoluene 0.10 0.10 0.1Dehydrated alcohol* q.s. q.s. q.s. Push Layer Polyethylene oxide(POLYOX ® 88.0 88.0 88.0 WSR 303) Sodium chloride 22.0 22.0 22.0Povidone (KOLLIDON ® 30 LP) 12.0 12.0 12.0 Stearic acid 0.50 0.50 0.5Butylated hydroxytoluene (BHT) 0.20 0.20 0.2 Red pigment blend 1.50 1.501.5 Dehydrated alcohol* q.s. q.s. q.s. Core Tablet Weight 550.0 550.0478.0 Functional Coating Layer OPADRY ® CA clear (95:5) 82.5 96.3 83.7Total Weight 632.5 646.3 561.7 *Removed during processTrilayer methylphenidate tablets were made according to the procedure asper Example 5. Tablets 35, 36, and 37 were tested for dissolution inabout 900 ml of about 0.01N HCl for up to 24 hours, using USP ApparatusII (Sinkers), with agitation at 50 rpm and 37° C. Percentage dissolutionof the tablets was measured at 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22,and 24 hours. FIG. 14 compares drug recovery between Tablets 35 and 36containing different amounts of sodium chloride in the active layer.Tablet 35, containing about 20 mg of sodium chloride in the activelayer, provides reduced lag time and higher drug recovery compared totablet 36, containing about 10 mg of sodium chloride, in the activelayer. The Figure demonstrates that presence of sodium chloride inactive layer improves drug recovery. The Figure further compares resultsbetween Tablets 35 and 37 containing POLYOX® 205 in the placebo layerand about 20 mg of sodium chloride in the active layer; and POLYOX® 1105in the placebo layer and about 10 mg of sodium chloride in the activelayer respectively. Tablet 35 containing POLYOX® 205 and about 20 mg ofsodium chloride provides reduced lag time and higher drug recoverycompared to Tablet 37 containing POLYOXO® 1105 and about 10 mg of sodiumchloride.

Example 14 Effect of POLYOX Amount in Push Layer on Lag Time

The present Example provides two delayed release methylphenidate tabletscomprising different amounts of POLYOX® in the push layer. Thecomponents of the two tablets are outlined below in Table 16.

TABLE 16 Tablet 38 Tablet 39 Composition mg/dose mg/dose Placebo LayerPolyethylene oxide (POLYOX ® N205) 150.0 150.0 Povidone (KOLLIDON ® 30LP) 8.0 8.0 Stearic acid 1.6 1.6 Butylated hydroxytoluene 0.20 0.20Dehydrated alcohol* q.s. q.s. Active Layer Methylphenidate HCl 54.0 54.0Polyethylene oxide (POLYOX ® N80) 187.0 187.0 Povidone (KOLLIDON ® 30LP) 4.0 4.0 Stearic acid 0.9 0.9 Butylated hydroxytoluene 0.10 0.10Sodium chloride 20.0 20.0 Dehydrated alcohol* q.s. q.s. Push LayerPolyethylene oxide (POLYOX ® WSR 303) 80.00 62.00 Sodium chloride 22.0015.5 Povidone (KOLLIDON ® 30 LP) 12.0 8.4 Stearic acid 0.50 0.40Butylated hydroxytoluene (BHT) 0.20 0.10 Red pigment blend 1.50 1.10Dehydrated alcohol* q.s. q.s. Core Tablet Weight 550.0 514.0 FunctionalCoating Layer OPADRY ® CA clear (95:5) 82.50 77.1 Total Weight 632.5591.1 *Removed during processTrilayer methylphenidate tablets were made according to the proceduredescribed per Example 5. Tablets 38 and 39 were tested for dissolutionin about 900 ml of about 0.01N HCl for up to 24 hours, using USPApparatus II (Sinkers), with agitation at 50 rpm and 37° C. Percentagedissolution of the tablets was measured at 2, 4, 6, 8, 10, 12, 14, 16,18, 20, 22, and 24 hours. FIG. 15 shows effect of POLYOX® amount in pushlayer on lag time in a composition with a drug: polymer weight ratio inthe active layer of about 20:80. The Figure demonstrates that the lagtime decreases with increasing the amount of POLYOX® in push layer.

Example 15 Effect of pH on Lag Time

The present Example provides a delayed release methylphenidate tabletcomprising a placebo layer, a single active layer, a push layer, and afunctional coating layer. The components of the tablet are outlinedbelow in Table 17.

TABLE 17 Tablet 40 Composition mg/dose Placebo layer Polyethylene oxide(POLYOX ® N205) 150.0 Povidone (KOLLIDON ® 30 LP) 8.0 Stearic acid 1.6Butylated hydroxytoluene 0.20 Dehydrated alcohol* q.s. Active layerMethylphenidate HCl 54.0 Polyethylene oxide (POLYOX ® N80) 125.0Povidone (KOLLIDON ® 30 LP) 4.0 Stearic acid 0.9 Butylatedhydroxytoluene 0.10 Sodium chloride 10.0 Dehydrated alcohol* q.s. Pushlayer Polyethylene oxide (POLYOX ® WSR 303) 88.0 Sodium chloride 22.00Povidone (KOLLIDON ® 30 LP) 12.0 Stearic acid 0.50 Butylatedhydroxytoluene (BHT) 0.10 Red pigment blend 1.60 Dehydrated alcohol*q.s. Core Tablet Weight 478.0 Functional Coating Layer OPADRY ® CA clear(95:5) 71.7 Total Weight 549.7 *Removed during processTrilayer methylphenidate tablets were made according to the procedure asper Example 5. Tablet 40 was tested for dissolution in about 900 ml ofabout 0.01N HCl, pH 4.5 acetate buffer, and pH 6.8 phosphate buffer, forup to 24 hours, using USP Apparatus II (Sinkers), with agitation at 50rpm and 37° C. Percentage dissolution of the tablet was measured at 2,4, 6, 8, 10, 12, 14, 16, 18, 20, 22, and 24 hours. FIG. 16 shows effectof pH on lag time in a tablet with a drug to polymer ratio of about30:70. The Figure demonstrates that the lag time does not change underdifferent pH conditions.

Example 16 Effect of Push Layer Amount on Lag Time

The present Example provides two delayed release methylphenidate tabletswith different amounts of components in the push layer and thefunctional coating layer. The components of the two tablets are outlinedbelow in Table 18.

TABLE 18 Tablet 41 Tablet 42 Composition mg/dose mg/dose Placebo LayerPolyethylene oxide (POLYOX ® 1105) 150.0 150.0 Povidone (KOLLIDON ® 30LP) 8.0 8.0 Stearic acid 1.6 1.6 Butylated hydroxytoluene 0.20 0.20Dehydrated alcohol* q.s. q.s. Active Layer Methylphenidate HCl 54.0 54.0Polyethylene oxide (POLYOX ® N80) 81.0 81.0 Povidone (KOLLIDON ® 30 LP)4.0 4.0 Stearic acid 0.9 0.9 Butylated hydroxytoluene 0.10 0.10 Sodiumchloride 10.0 10.0 Dehydrated alcohol* q.s. q.s. Push Layer Polyethyleneoxide (POLYOX ® WSR 303) 71.00 88.00 Sodium chloride 17.7 22.0 Povidone(KOLLIDON ® 30 LP) 12.0 8.4 Stearic acid 0.40 0.50 Butylatedhydroxytoluene (BHT) 0.10 0.10 Red pigment blend 1.3 1.6 Dehydratedalcohol* q.s. q.s. Core Tablet Weight 550.0 514.0 Functional CoatingLayer OPADRY ® CA clear (95:5) 61.5 65.1 Total Weight 471.5 499.1*Removed during processTrilayer methylphenidate tablets were made according to the procedure asper Example 5. Tablets 41 and 42 were tested for dissolution in about900 ml of about 0.01N HCl for up to 24 hours, using USP Apparatus II(Sinkers), with agitation at 50 rpm and 37° C.

Percentage dissolution of the tablets was measured at 2, 4, 6, 8, 10,12, 14, 16, 18, 20, 22, and 24 hours. FIG. 17 shows effect of push layeramount on lag time in tablets with drug to polymer ratio of about 40:60.The Figure demonstrates that an increase in push layer amount, fromabout 108.5 mg to about 120.6 mg, improves drug recovery to up to about93%, without affecting the lag time.

Example 17 Effect of Coating Level and Polymer Amount in Placebo Layeron Lag Time

The present Example provides four delayed release methylphenidatetablets. Tablets 43 and 43A, and Tablets 44 and 44A comprise differentamounts of POLYOX® 1105 in the placebo layer. Tablets 43 and 44 include12.5% coating weight gain, whereas Tablets 43A and 44A comprise 15%coating weight gain. The components of the four tablets are outlinedbelow in Table 19.

TABLE 19 Tablet 43 Tablet 44 Tablet 43A Tablet 44A Composition mg/dosemg/dose mg/dose mg/dose Placebo Layer POLYOX ® 1105 150.0 100.0 150.0100.0 Povidone 7.8 5.2 7.8 5.2 (Kollidon ® 30 LP) Stearic acid 1.5 1.01.5 1.0 Butylated hydroxytoluene 0.20 0.20 0.20 0.20 Cab-O-Sil ® 0.3 0.20.3 0.2 Red pigment blend 0.2 0.1 0.2 0.1 Dehydrated alcohol* q.s. q.s.q.s. q.s. Active Layer Methylphenidate HCl 54.0 54.0 54.0 54.0 POLYOX ®N80 81.0 81.0 81.0 81.0 Povidone 8.0 8.0 8.0 8.0 (Kollidon ® 30 LP)Stearic acid 0.9 0.9 0.9 0.9 Cab-O-Sil ® 0.4 0.4 0.4 0.4 Butylatedhydroxytoluene 0.10 0.10 0.10 0.10 Sodium chloride 10.0 10.0 10.0 10.0Dehydrated alcohol* q.s. q.s. q.s. q.s. Push Layer POLYOX ® WSR 30388.00 88.00 88.00 88.00 Sodium chloride 22.0 22.0 22.0 22.0 Povidone12.0 12.0 12.0 12.0 (Kollidon ® 30 LP) Stearic acid 0.50 0.50 0.50 0.50Butylated hydroxytoluene 0.20 0.20 0.20 0.20 (BHT) Red pigment blend 1.51.5 1.5 1.5 Cab-O-Sil ® 0.3 0.3 0.3 0.3 Dehydrated alcohol* q.s. q.s.q.s. q.s. Core Tablet Weight 439.0.0 385.3 439.0.0 385.3 FunctionalCoating Layer Opadry CA clear (95:5) 54.87 48.16 65.85 57.75 TotalWeight 493.87 433.46 504.80 443.05 *Removed during processTrilayer methylphenidate tablets were made according to the procedure asper Example 5. All tablets were tested for dissolution in about 900 mlof about 0.01N HCl for up to 24 hours, using USP Apparatus II (Sinkers),with agitation at 50 rpm and 37° C. Percentage dissolution of thetablets was measured at 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, and 24hours. FIG. 18 shows effect of polymer amount in the placebo layer andcoating weight gain/coating level of the tablet, containing adrug:polymer weight ratio of about 40:60, on lag time. The Figuredemonstrates that higher polymer amounts in placebo layer and highercoating level on tablet increases lag time.

Example 18 Effect of pH and Viscosity of Dissolution Medium on Lag Time

The present Example provides a delayed release methylphenidate tabletcomprising a placebo layer, a single active layer, a push layer and afunctional coating layer. The components of the tablet are outlinedbelow in Table 20.

TABLE 20 Tablet 45 Composition mg/dose Placebo Layer Polyethylene oxide(POLYOX ® 1105) 100.0 Povidone (KOLLIDON ® 30 LP) 5.2 Stearic acid 1.0Butylated hydroxytoluene 0.20 Cab-O-Sil ® 0.3 Dehydrated alcohol* q.s.Active layer Methylphenidate HCl 54.0 Polyethylene oxide (POLYOX ® N80)81.0 Povidone (KOLLIDON ® 30 LP) 8.0 Stearic acid 0.9 Cab-O-Sil ® 0.4Butylated hydroxytoluene 0.10 Sodium chloride 10.0 Dehydrated alcohol*q.s. Push layer Polyethylene oxide (POLYOX ® WSR 303) 88.00 Sodiumchloride 22.0 Povidone (KOLLIDON ® 30 LP) 12.0 Stearic acid 0.50Butylated hydroxytoluene (BHT) 0.20 Red pigment blend 1.5 Cab-O-Sil ®0.3 Dehydrated alcohol* q.s. Core Tablet Weight 385.3 Functional CoatedLayer OPADRY ® CA (95:5) 48.16 Total Weight 433.46 *Removed duringprocessTrilayer methylphenidate tablets were made according to the procedure asper Example 5. Tablet 45 was tested for dissolution in about 900 ml ofabout 0.01N HCl, about 900 ml of pH 4.5 acetate buffer, and about 900 mlof pH 6.8 phosphate buffer, for up to 24 hours, using USP Apparatus II(Sinkers), with agitation at 50 rpm and 37° C. Percentage dissolution ofthe tablets was measured at 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, and24 hours. FIG. 19 compares dissolution rate of Tablet 45 at pH about 2,pH about 4.5, and pH about 6.8. The Figure demonstrates that lag timedoes not change with pH of the dissolution medium. FIG. 20 providesdissolution rate of Tablet 45 in dissolution mediums with differentviscosities. The Figure demonstrates that there is no change in lag timewith changes in viscosity of the dissolution medium.

Example 19 Effect of Discrimination Methods on Lag Time

Dissolution rates of Tablet 45 were compared using USP Apparatus II(Sinkers) with agitation at 50 rpm and temperature of 37° C., and usingUSP Apparatus III (Biodis) with agitation at 25 dpm and a temperature of37° C., mimicking effect of stomach shear on dissolution rate of thecomposition. Tablets 45 were placed individually in about 900 ml ofabout 0.01N HCl for up to 24 hours, in USP Apparatus II (Sinkers) withagitation at 50 rpm and a temperature of 37° C., and in about 250 ml ofabout 0.01 N HCl for up to 24 hours, in USP Apparatus III (Biodis) withagitation at 25 dpm and a temperature of 37° C. Percentage dissolutionof the tablets was measured at 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22,and 24 hours using the two methods. FIG. 21 compares dissolution rate ofTablet 45, containing a drug:polymer weight ratio of about 40:60, usingthe above two methods. The Figure demonstrates that there is nosubstantial change in lag time with changing hydrodynamics of thedissolution medium.

Example 20 Effect of Sodium Chloride Amount in the Placebo Layer on LagTime and Release Rate

The present Example provides three delayed release methylphenidatetablets comprising different amounts of sodium chloride in the placebolayer. The components of the three tablets are outlined below in Table21.

TABLE 21 Tablet 44 Tablet 46 Tablet 47 Composition mg/dose mg/dosemg/dose Placebo Layer Polyethylene oxide (POLYOX ® 1105) 100.0 100.0100.0 Povidone (KOLLIDON ® 30 LP) 5.2 5.2 5.2 Stearic acid 1.0 1.0 1.0Sodium chloride — 5.33 10.67 Butylated hydroxytoluene 0.20 0.20 0.2Cab-O-Sil ® 0.3 0.2 0.2 Red pigment blend 0.1 0.1 0.1 Dehydratedalcohol* q.s. q.s. q.s. Active Layer Methylphenidate HCl 54.0 54.0 54.0Polyethylene oxide (POLYOX ® N80) 81.0 81.0 81.0 Povidone (KOLLIDON ® 30LP) 8.0 8.0 8.0 Stearic acid 0.9 0.9 0.9 Cab-O-Sil ® 0.4 0.4 0.4Butylated hydroxytoluene 0.10 0.10 0.10 Sodium chloride 10.0 10.0 10.0Dehydrated alcohol* q.s. q.s. q.s Push Layer Polyethylene oxide 88.0088.00 88.00 (POLYOX ® WSR 303) Sodium chloride 22.0 22.0 22.0 Povidone(KOLLIDON ® 30 LP) 12.0 12.0 12.0 Stearic acid 0.50 0.50 0.50 Butylatedhydroxytoluene (BHT) 0.20 0.20 0.20 Red pigment blend 1.5 1.5 1.5Cab-O-Sil ® 0.3 0.3 0.3 Dehydrated alcohol* q.s.. q.s. q.s. Core TabletWeight 385.7 390.93 396.27 Functional Coating Layer OPADRY ® CA (95:5)48.16 48.83 49.49 Total Weight 433.86 439.76 445.76 *Removed duringprocessTrilayer methylphenidate tablets were made according to the procedure asper Example 5. Tablets 44, 46, and 47 were tested for dissolution inabout 900 ml of about 0.01N HCl for up to 24 hours, using USP ApparatusII (Sinkers), with agitation at 50 rpm and 37° C. Percentage dissolutionof the tablets was measured at 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22,and 24 hours. FIG. 22 shows effect of sodium chloride in placebo layeron lag time and release rate. The Figure demonstrates that presence ofsodium chloride in placebo layer has negligible effect on lag time andrelease rate.

Example 21 Effect of POLYOX® Grade in Placebo Layer on Lag Time

The present Example provides three delayed release methylphenidatetablets comprising different grades of POLYOX® in the placebo layer. Thecomponents of the three tablets are outlined below in Table 22.

TABLE 22 Tablet 44 Tablet 48 Tablet 49 Composition mg/dose mg/dosemg/dose Placebo Layer Polyethylene oxide (POLYOX ® 1105) 100.0 — —Polyethylene oxide (POLYOX ® N750) 100.0 Polyethylene oxide (POLYOX ®N80) 100.0 Povidone (KOLLIDON ® 30 LP) 5.2 5.2 5.2 Stearic acid 1.0 1.01.0 Sodium chloride — — — Butylated hydroxytoluene 0.20 0.20 0.2Cab-O-Sil ® 0.3 0.2 0.2 Red pigment blend 0.1 0.1 0.1 Dehydratedalcohol* q.s. q.s. q.s. Active Layer Methylphenidate HCl 54.0 54.0 54.0Polyethylene oxide (POLYOX ® N80) 81.0 81.0 81.0 Povidone (KOLLIDON ® 30LP) 8.0 8.0 8.0 Stearic acid 0.9 0.9 0.9 Cab-O-Sil ® 0.4 0.4 0.4Butylated hydroxytoluene 0.10 0.10 0.10 Sodium chloride 10.0 10.0 10.0Dehydrated alcohol* q.s. q.s. q.s Push Layer Polyethylene oxide 88.0088.00 88.00 (POLYOX ® WSR 303) Sodium chloride 22.0 22.0 22.0 Povidone(KOLLIDON ® 30 LP) 12.0 12.0 12.0 Stearic acid 0.50 0.50 0.50 Butylatedhydroxytoluene (BHT) 0.20 0.20 0.20 Red pigment blend 1.5 1.5 1.5Cab-O-Sil ® 0.3 0.3 0.3 Dehydrated alcohol* q.s.. q.s. q.s. Core TabletWeight 385.7 385.7 385.7 Functional Coating Layer OPADRY ® CA (95:5)48.16 48.16 48.16 Total Weight 433.86 433.86 433.86 *Removed duringprocessTrilayer methylphenidate tablets were made according to the procedure asper Example 5. Tablets 44, 48, and 49 were tested for dissolution inabout 900 ml of about 0.01N HCl for up to 24 hours, using USP ApparatusII (Sinkers), with agitation at 50 rpm and 37° C. Percentage dissolutionof the tablets was measured at 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22,and 24 hours. FIG. 23 shows the effect of POLYOX® grade in placebo layeron lag time. The Figure compares lag time in compositions containingPOLYOX® 80 (200K), POLYOX® 750 (300K), and POLYOX® 1105 (900K) inplacebo layer. The Figure demonstrates that the average molecular weightof POLYOX® in the placebo layer should be at least about 300K to providea lag time of at least about 6 hours.

Example 22 Effect of POLYOX® Grade in Push Layer on Lag Time

The present Example provides three delayed release methylphenidatetablets comprising different grades of POLYOX® in the push layer. Thecomponents of the three tablets are outlined below in Table 23.

TABLE 23 Tablet 44 Tablet 50 Tablet 51 Composition mg/dose mg/dosemg/dose Placebo Layer Polyethylene oxide (POLYOX ® 1105) 100.0 — —Polyethylene oxide (POLYOX ® N750) 100.0 Polyethylene oxide (POLYOX ®N80) 100.0 Povidone (KOLLIDON ® 30 LP) 5.2 5.2 5.2 Stearic acid 1.0 1.01.0 Sodium chloride — — — Butylated hydroxytoluene 0.20 0.20 0.2Cab-O-Sil ® 0.3 0.2 0.2 Red pigment blend 0.1 0.1 0.1 Dehydratedalcohol* q.s. q.s. q.s. Active Layer Methylphenidate HCl 54.0 54.0 54.0Polyethylene oxide (POLYOX ® N80) 81.0 81.0 81.0 Povidone (KOLLIDON ® 30LP) 8.0 8.0 8.0 Stearic acid 0.9 0.9 0.9 Cab-O-Sil ® 0.4 0.4 0.4Butylated hydroxytoluene 0.10 0.10 0.10 Sodium chloride 10.0 10.0 10.0Dehydrated alcohol* q.s. q.s. q.s Push Layer Polyethylene oxide 88.00 —— (POLYOX ® WSR 303) Polyethylene oxide — 88.0 — (POLYOX ® WSR 301)Polyethylene oxide (POLYOX ® WSR — — 88.0 Coagulant) Sodium chloride22.0 22.0 22.0 Povidone (KOLLIDON ® 30 LP) 12.0 12.0 12.0 Stearic acid0.50 0.50 0.50 Butylated hydroxytoluene (BHT) 0.20 0.20 0.20 Red pigmentblend 1.5 1.5 1.5 Cab-O-Sil ® 0.3 0.3 0.3 Dehydrated alcohol* q.s.. q.s.q.s. Core Tablet Weight 385.7 385.7 385.7 Functional Coating LayerOPADRY ® CA (95:5) 48.16 48.16 48.16 Total Weight 433.86 433.86 433.86*Removed during processTrilayer methylphenidate tablets were made according to the procedure asper Example 5. Tablets 44, 50, and 51 were tested for dissolution inabout 900 ml of about 0.01N HCl for up to 24 hours, using USP ApparatusII (Sinkers), with agitation at 50 rpm and 37° C. Percentage dissolutionof the tablets was measured at 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22,and 24 hours. FIG. 24 shows the effect of POLYOX® grade in the pushlayer on release rate and drug recovery. The Figure compares releaserate and drug recovery in compositions containing POLYOX® WSR 303 (7M),POLYOX® WSR 301 (3M), and POLYOX® WSR Coagulant (5M) in push layer. TheFigure demonstrates that compositions containing POLYOX® WSR 301 orPOLYOX® WSR Coagulant in the push layer provide faster release profileand lower drug recovery, compared to compositions containing POLYOX® 303in the push layer.

Example 23 Effect of Presence of Disintegrant and Sodium Chloride inPlacebo Layer

The present Example provides two delayed release methylphenidate tabletswith or without sodium chloride, sylloid and croscarmellose sodium inthe placebo layer. The components of the three tablets are outlinedbelow in Table 24.

TABLE 24 Tablet 52 Tablet 53 Composition mg/dose mg/dose Placebo LayerPolyethylene oxide (POLYOX ® 1105) 100.0 100.0 Povidone (KOLLIDON ® 30LP) 5.20 5.20 Stearic acid 1.00 1.0 Butylated hydroxytoluene 0.13 0.13Cab-O-Sil ® 0.27 0.27 Red Pigment blend 0.07 0.07 Croscarmellose sodium4.00 — Sylloid 2.60 — Sodium chloride 19.9 — Dehydrated alcohol* q.s.q.s. Active layer Methylphenidate HCl 54.0 54.0 Polyethylene oxide(POLYOX ® N80) 81.0 36 Povidone (KOLLIDON ® 30 LP) 7.60 5.1 Stearic acid0.90 0.55 Cab-O-Sil ® 0.40 0.28 Butylated hydroxytoluene 0.10 0.07Sodium chloride 10.0 6.70 Dehydrated alcohol* q.s. q.s. Push layerPolyethylene oxide (POLYOX ® WSR 88.00 88.0 Coagulant) Sodium chloride22.0 22.0 Povidone (KOLLIDON ® 30 LP) 12.0 12.0 Stearic acid 0.50 0.50Butylated hydroxytoluene (BHT) 0.20 0.20 Red pigment blend 1.5 1.5Cab-O-Sil ® 0.3 0.30 Dehydrated alcohol* q.s. q.s. Core Tablet Weight411.67 333.87 Functional Coating OPADRY ® CA (95:5) 51.46 41.73 TotalWeight 463.13 375.60 *Removed during processTrilayer methylphenidate tablets were made according to the procedure asper Example 5. Tablets 52 and 53 were tested for dissolution in about900 ml of about 0.01N HCl, using USP Apparatus II (Sinkers), withagitation at 50 rpm and 37° C. Percentage dissolution of the tablet wasmeasured at 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, and 24 hours. FIG.25 compares dissolution rate of Tablet 52 and Tablet 53. The Figuredemonstrates that addition of a superdisintegrant and sodium chloride inthe placebo layer, reduces drug recovery without affecting lag time.

In addition to the various embodiments depicted and claimed, thedisclosed subject matter is also directed to other embodiments havingother combinations of the features disclosed and claimed herein. Assuch, the particular features presented herein can be combined with eachother in other manners within the scope of the disclosed subject mattersuch that the disclosed subject matter includes any suitable combinationof the features disclosed herein. The foregoing description of specificembodiments of the disclosed subject matter has been presented forpurposes of illustration and description. It is not intended to beexhaustive or to limit the disclosed subject matter to those embodimentsdisclosed.

It will be apparent to those skilled in the art that variousmodifications and variations can be made in the systems and methods ofthe disclosed subject matter without departing from the spirit or scopeof the disclosed subject matter. Thus, it is intended that the disclosedsubject matter include modifications and variations that are within thescope of the appended claims and their equivalents.

Various patents and patent applications are cited herein, the contentsof which are hereby incorporated by reference herein in theirentireties.

1-76. (canceled)
 77. An osmotic-controlled oral pharmaceuticalcomposition providing delayed release of a therapeutically effectiveamount of a drug, the composition comprising: a) a multilayered corecomprising a placebo layer, an active layer, and a push layer, wherein:(i) the placebo layer comprises at least one low molecular weightpolyethylene oxide polymer having an average molecular weight of fromabout 600K to about 900K, or intermediate values thereof, (ii) theactive layer comprises a drug, and at least one low molecular weightpolyethylene oxide polymer having an average molecular weight of lessthan or equal to 300K, (iii) the push layer comprises an osmogen and atleast one high molecular weight polyethylene oxide polymer having anaverage molecular weight of greater than or equal to 1M; and b) asemipermeable membrane, containing an orifice and surrounding the core,wherein the layers in the multilayer core are placed in the followingorder: the placebo layer in fluid communication with the orifice in thesemipermeable membrane; the active layer; and the push layer facing awayfrom the orifice, wherein the drug has a molecular weight of less than900, wherein the composition provides a lag time of at least 6 hoursduring which the composition releases no more than 10% of the activepharmaceutical ingredient.
 78. The composition of claim 77, wherein thedrug is selected from the group consisting of amphetamines,methylphenidate, diltiazem, carbamazepine, metoprolol, oxprenolol,nifedipine, albuterol, phenylpropanolamine, pseudoephedrine,chlorpheniramine maleate, prazosin, doxazosin, verapamil, oxybutyninchloride, isradipine, hydromorphone, paliperidone, modafinil,armodafinil, liothyronine, oseltamivir (Tamiflu), rifamycin, andglipizide.
 79. The composition of claim 77, wherein the compositionexhibits minimal variability in the lag time with variations in pH,volume and/or viscosity of a dissolution medium.
 80. The composition ofclaim 77, wherein the semipermeable membrane comprises a pH-independentwater-insoluble polymer and a pH-independent pore former at a polymer topore former ratio of between about 80:20 and about 99.5:0.5.
 81. Thecomposition of claim 80, wherein the pH-independent water-insolublepolymer in the semipermeable membrane comprises polymers selected fromthe group consisting of cellulose acetate, cellulose acetate butyrate,and cellulose triacetate.
 82. The composition of claim 80, wherein thepore former is selected from the group comprising polyethylene glycol,hydroxypropyl cellulose, polyvinyl pyrolidone, polyvinyl acetate,mannitol, and methyl cellulose, poloxamer, triethyl citrate, triacetin,hydroxypropyl methylcellulose, glycerol, and combinations thereof. 83.The composition of claim 80, wherein the semipermeable membrane furthercomprises at least one plasticizer selected from the group consisting ofpolyethylene glycols, triethyl citrate, triacetin, diethyl tartrate, andcombinations thereof.
 84. The composition of claim 77, wherein thepolyethylene oxide polymer in the placebo layer has an average molecularweight of about 600K or about 900K, and the polyethylene oxide polymerin the active layer has an average molecular weight of about 200K. 85.The composition of claim 77, wherein the polyethylene oxide polymer inthe push layer has an average molecular weight of about 1M, about 2M,about 4M, about 5M, about 7M, or intermediate values therein.
 86. Thecomposition of claim 77, wherein the osmogen in the push layer isselected from the group consisting of sodium chloride, potassiumchloride, potassium sulfate, lithium sulfate, sodium sulfate, lactoseand sucrose combination, lactose and dextrose combination, sucrose,dextrose, mannitol, dibasic sodium phosphate, or combinations thereof.87. The composition of claim 77, wherein the osmogen in the push layeris present in an amount of between about 5 wt % and about 30 wt % of thepush layer.
 88. The composition of claim 77, wherein the semipermeablemembrane is applied with a coating weight gain of between 10 wt % and 20wt % of the multilayered core.
 89. The composition of claim 77, whereinthe composition provides drug recovery of at least about 90% at about 22hours, from the time of administration into a dissolution medium.
 90. Anosmotic-controlled oral pharmaceutical composition providing delayedrelease of a therapeutically effective amount of a drug, the compositioncomprising: a) a multilayered core comprising a placebo layer, an activelayer, and a push layer, wherein: (i) the placebo layer comprises atleast one low molecular weight polyethylene oxide polymer having anaverage molecular weight of from about 600K to about 900K, orintermediate values thereof, (ii) the active layer comprises a drug andat least one low molecular weight polyethylene oxide polymer having anaverage molecular weight of less than or equal to 300K, (iii) the pushlayer comprises an osmogen and at least one high molecular weightpolyethylene oxide polymer having an average molecular weight of greaterthan or equal to 1M; and b) a semipermeable membrane, containing anorifice and surrounding the core, wherein the layers in the multilayercore are placed in the following order: the placebo layer in fluidcommunication with the orifice in the semipermeable membrane; the activelayer; and the push layer facing away from the orifice, wherein the drughas a molecular weight of less than 900, wherein the drug: polymer ratioin the active layer is between 40:60 and 60:40, wherein the compositionprovides a lag time of at least 6 hours during which the compositionreleases no more than 10% of the active pharmaceutical ingredient,followed by extended release of the active agent for about 10-16 hours.91. The composition of claim 90, wherein the osmogen in the push layeris present in an amount of between about 5 wt % and about 30 wt % of thepush layer.
 92. The composition of claim 90, wherein the semipermeablemembrane comprises a pH-independent water-insoluble polymer and apH-independent pore former at a polymer to pore former ratio of betweenabout 80:20 and about 99.5:0.5.
 93. The composition of claim 90, whereinthe semipermeable membrane is applied with a coating weight gain ofbetween 10 wt % and 20 wt % of the multilayered core.
 94. Anosmotic-controlled oral pharmaceutical composition providing delayedrelease of a therapeutically effective amount of a drug, the compositioncomprising: a) a multilayered core comprising a placebo layer, an activelayer, and a push layer, wherein: (i) the placebo layer comprises atleast one low molecular weight polyethylene oxide polymer having anaverage molecular weight of from about 600K to about 900K, orintermediate values thereof, (ii) the active layer comprises a drug andat least one low molecular weight polyethylene oxide polymer having anaverage molecular weight of less than or equal to 300K, (iii) the pushlayer comprises an osmogen and at least one high molecular weightpolyethylene oxide polymer having an average molecular weight of greaterthan or equal to 1M; and b) a semipermeable membrane, containing anorifice and surrounding the core, wherein the layers in the multilayercore are placed in the following order: the placebo layer in fluidcommunication with the orifice in the semipermeable membrane; the activelayer; and the push layer facing away from the orifice, wherein the drughas a molecular weight of less than 900, wherein the semipermeablemembrane comprises a pH-independent water-insoluble polymer and apH-independent pore former at a polymer to pore former ratio of betweenabout 80:20 and about 99.5:0.5, and wherein the composition provides alag time of at least 6 hours during which the composition releases nomore than 10% of the active pharmaceutical ingredient.
 95. Thecomposition of claim 94, wherein the semipermeable membrane is appliedwith a coating weight gain of between 10 wt % and 20 wt % of themultilayered core.
 96. The composition of claim 94, wherein the osmogenin the push layer is present in an amount of between about 5 wt % andabout 30 wt % of the push layer